

# Index to Volume 37

The index to Volume 37 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in the *Journal* as "index terms" following abstracts.) IPA covers all authored papers in *AJHP* as well as selected letters, editorials, and news reports. Items that were published in the ASHP Reports section, including official ASHP statements and guidelines, are indexed under "American Society of Hospital Pharmacists." The subject index also notes all regular *Journal* columns and, under the respective column headings, the titles of items in the "Questions and Answers," "Editorials," and "Book Reviews" sections; the items covered in "Equipment and Supplies," the individual reports from affiliated chapters in "ASHP Affiliates," and the titles of individual stories in "News." Under "News," items covered in "Appointments and Promotions" and in "News Briefs" are listed after those subheadings. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page number on which the correction appeared.

Issue	Pages
January	1-140
February	141-310
March	311-440
April	441-600
May	601-748
June	749-896

Issue	Pages
July	897-1028
August	1029-1156
September	1157-1272
October	1273-1436
November	1437-1584
December	1585-1740

## Subject Index

**A**

**Acetaminophen:** interactions; tests; laboratory, phosphotungstate uric acid, discussion, 1458

**Acetone:** combination, alcohol, ethyl, denatonium benzoate, isopropylacetone; incompatibilities, povidone-iodine, loss of free iodine, 464

**Acidifying agents:** ascorbic acid; lack, effects, urinary pH, spinal cord injury and neurogenic bladder patients, 235

**Additives**

dextrose; diazepam, 496; diazepam, injections, i.v., 492; injections, stability, effects, cellulose ester membrane filters, 935; nitroglycerin, incompatibilities, containers, polyvinyl chloride, polyolefin, glass, 618

effects; incompatibilities, sodium phosphate and calcium chloride or calcium gluconate, FreAmine II solutions, 673

injections; antineoplastic agents, manufacturing, hospital pharmacy, equipment, 1184; carmustine, incompatibilities, sodium chloride or dextrose, alone and with sodium bicarbonate, room temperature, 677; cimetidine, hydrochloride, stability, visual and chemical, 390; incompatibilities, beryllium tosylate, glass and plastic containers, 803; incompatibilities, dobutamine, hydrochloride, visual, 400; incompatibilities, edetate disodium, possible, discussion, 174; incompatibilities, lack, verapamil hydrochloride, glass and plastic containers, 676; intravenous, phenytoin sodium, stability, comparison, dextrose and sodium chloride, 95; iron dextran, stability, parenteral nutrient formulations, 206; mixing, polyvinyl chloride bags, methods, 1610; nitroglycerin, incompatibilities, containers, polyvinyl chloride, polyolefin, glass, 618; phenytoin sodium, precipitation, large volume parenteral, 1647; stability, effects, cellulose ester membrane filters, 935; procainamide, stability, water and dextrose, combination, sodium chloride, 1050

Ringer's injection lactated; diazepam, injections, 496

sodium chloride; diazepam, injections, i.v., 492; injections, stability, effects, cellulose ester membrane filters, 935; nitroglycerin, incompatibilities, containers, polyvinyl chloride, polyolefin, glass, 618

**Additives, see also Admixtures**

**Administration**

hospital pharmacy; Canada, discussion, 501; drug distribution systems, unit dose, audits, 85; quality assurance, programs, management corporation, 82

management; hospital pharmacy, 21st century, discussion, 355

personnel, pharmacy; supportive, technicians, job satisfaction, 359

pharmacists; education, anticoagulants, patients, programs, audit, 89

**Admixtures**

cefazolin sodium; stability, thawing, microwave radiation, 211

injections; control, quality, sterility, cumulative sum control chart, 658; hospitals, shared, small rural, 1534; intravenous, centralized, hospital, services, guidelines, quality assurance, 645; intravenous, quality control, visual inspection and environmental testing, 189; personnel, control, quality, microbiological contamination, aseptic operator technique, 668

**Admixtures, see also Additives**

**Adsorption**

diazepam; containers, and administration sets, injections,

i.v., 492; containers, and administration sets, injections, i.v., 496

filters; membrane, cellulose ester, additives, effects, stability, 935

insulin; containers, i.v., glass and plastics, effects, blood, 1323

**Advertising Index**, 140, 310, 440, 600, 748, 896, 1028, 1156, 1272, 1436, 1584, 1714

**AJHP Continuing Education**, 7, 147, 319, 447, 609, 755, 903, 1038, 1165, 1279, 1443, 1591

**Alanine:** incompatibilities; lack, parenteral nutrition, formulations, 1620

**Alcohols:** interactions; cefoperazone, facial flushing, tachycardia, diaphoresis, patient, 858

**Alcohols, benzyl:** diluents; iron dextran, formulations, 206

**Alcohols, ethyl:** combination, acetone, denatonium benzoate, isopropylacetone; incompatibilities, povidone-iodine, loss of free iodine, 464

**Ambulatory care**

clinics; pediatric, clinical and distributive pharmacy services, 1339

patients, clinic, rational therapy, pharmacists, role, comparison, physician assessment, 824

pharmacists, hospital; role, 801

**American Journal of Hospital Pharmacy**

acknowledgment to reviewers, 1663

notice to authors, 248

statement of ownership, management, and circulation, 1495

survey of readers, 534

**American Society of Hospital Pharmacists**

accreditation standard for residency training in clinical pharmacy (with guide to interpretation), 1223

accreditation standard for specialized pharmacy residency training (with guide to interpretation), 1229

affiliated state chapter officers, 994

ASHP and ANA guidelines for collaboration of pharmacists and nurses in institutional care settings, 253

Board of Directors; actions, November 15-16, 1979 meeting, 254; March 20, 1980 meeting, 1094; April 19, 1980 meeting, 1095; September 25-26, 1980 meeting, 1685

Council on Clinical Pharmacy and Therapeutics, report of, 981

Council on Education and Manpower; report of, 982

Council on Legal and Public Affairs; report of, 983

Council on Organizational Affairs; report of, 986

Council on Professional Affairs; report of, 988

Executive Vice President; report of, 976

guidelines on hospital drug distribution and control (with references), 1097

Harvey A. K. Whitney Lecture Award; 1979, 355

House of Delegates, 31st annual session; members of, 968; proceedings of, 965

legislative alert system; pharmacists, hospital, participation, discussion, 160

long-range position statement on pharmacy manpower needs and residency training, 1220

membership; predictions, 21st century, 355

Midyear Clinical Meeting, 1980; program, 1370

officers, directors, councils, and committees; directory of, 990

practice spotlight program, 959

President and Chairman of the Board; report of, 969

President-elect and Vice Chairman of the Board; report of, 972

residents in training in accredited programs; calendar

year 1979, 690

statement of goals for institutional pharmacy, 1095

statement on accreditation of pharmacy residencies (with policies and procedures), 1221

statement on clinical pharmacy and its relationship to the institution, 1096

statement on the provision of pharmaceutical services in ambulatory care settings, 1096

supplementary standard and learning objectives for residency training in psychiatric pharmacy practice (supplement to the ASHP accreditation standard for specialized pharmacy residency training), 1232

Task Force on Payment for Pharmacy Services, summary of final report, 393

Treasurer; report of, 978

**Amikacin:** pharmacokinetics; weight, effects, morbidly obese patients, 519

**Amin-Aid:** incompatibilities; plastics, containers, disinfection, 464

**Amino acids:** nutrition, parenteral; solutions pH, titration curves, 388

**Aminoacetic acid:** incompatibilities; lack, parenteral nutrition, formulations, 1620

**Aminoglycosides**

antibiotics; calculators, dosage schedules and blood levels, 225

blood levels; analysis, role, clinical pharmacists, 61

**Aminophylline**

dosage forms; solids, stability, following unit dose repackaging in hospital pharmacy, 165

interactions; tests, laboratory, phosphotungstate uric acid, lack, patients, 1522

tablets; availability, patients, 1618; stability, packaging, unit dose, cellophane, 1046

**Aminosilicic acid:** interactions; tests, laboratory, interference, 12-channel autoanalyzer, 1333

**Aminosyn:** additives; cimetidine hydrochloride, stability, visual and chemical, 390

**Ampicillin:** concomitant therapy; patient, 1551

**Ampicillin:** package inserts; patients, pharmacists, hospital, legal implications, 1656

**Analgesics:** migraine therapy; review, 365

**Analgesics and antipyretics:** pentazocine hydrochloride; injections, stability, room temperature, following repackaging, 680

**Analysis**

dipoxin; blood levels, rational therapy, hospitals, 1466

tobramycin; blood levels, effects, carbenicillin interaction, patient, 702

**Anesthetics, local:** lidocaine; iontophoresis, comparison, swabbing, SC, patients, 843

**Antacids:** ulcers; stress, therapy, review, 1651

**Anthralin:** topical therapy; psoriasis, review, 814

**Antibiotics**

aminoglycosides; calculators, dosage schedules and blood levels, 225

cefoperazone; interactions, alcohols, ethyl, adverse reactions, facial flushing, tachycardia, diaphoresis, patient, 858

dosage schedules; computer, pharmacokinetics, meningitis or bacteremia patients, 525; pharmacokinetics, methodology, 1366

rational therapy; effects, clinical pharmaceutical services, hospitals, 829

**Antibodies:** insulin; mechanism of action, patients, 1155

**Anticoagulants**

education; patients, programs, by pharmacists, audit,

- heparin; injections, i.v. effects, drop size, administration sets, 1346; injections, i.v., stability, lack, effects, cellulose ester membrane filters, 935
- warfarin; interactions, doxycycline, increased coagulation, patient, 1620; package inserts, patients, pharmacists, hospital, legal implications, 1656
- warfarin sodium; patient information, comprehension, effects, reading levels, and attitude, 240
- Anticonvulsants**
- carbamazepine; leukocytosis, patient, 550
- paramethadione; interactions, tests, laboratory, interference, 12-channel autoanalyzer, 1333
- phenytoin; dosage schedules, calculators, programmable, prediction, 529; dosage schedules, methodology, pharmacokinetics, 128; dosage schedules, pharmacokinetics, computers, models, blood levels vs time profiles, patients, 1631; package inserts, patients, pharmacists, hospital, legal implications, 1656; suspensions, oral stability, room temperature, following repackaging, 680
- phenytoin sodium; dosage, single, oral, pharmacokinetics and side effects, patients, 232; stability, i.v., additives, comparison, dextrose and sodium chloride, 96; stability, additives, precipitation, large volume parenterals, 1647
- therapy; forms, blood levels and dosage, inpatients, 772
- Antidepressants**; tricyclic; migraine therapy, review, 365
- Antidiabetic agents**; tolbutamide; tablets, equivalency, generic, dissolution characteristics, 1329
- Antidiarrheal agents**; colitis, ulcerative; therapy, review, 1635
- Antihistamines**
- promethazine hydrochloride; injections, stability, room temperature, following repackaging, 680
- rhinitis, vasomotor; therapy, discussion, 1496
- triprolidine, combination, pseudoephedrine hydrochloride; dosage forms, solids, stability, following unit dose repackaging in hospital pharmacy, 165
- Anti-infective agents**
- dosage schedules; computers, pharmacokinetics, meningitis or bacteremia patients, 523
- rational therapy; effects, clinical pharmaceutical services, hospitals, 829
- Antilipemic agents**; clofibrate; package inserts, patients, pharmacists, hospital, legal implications, 1656
- Antineoplastic agents**
- bleomycin sulfate; injections, i.v., stability, lack, effects, cellulose ester membrane filters, 935
- fluorouracil; stability, solutions, amber glass containers, effects, temperature, pH, 164
- injections; manufacturing, hospital pharmacy, equipment, 1184
- interactions; lithium carbonate, neutropenia, cancer patients, 1066
- labeling; pharmacist, and nurses, role, hospitals, 1617
- vinblastine sulfate; injections, stability, lack, effects, cellulose ester membrane filters, 935
- vincristine sulfate; infections, stability, effects, cellulose ester membrane filters, 935
- Antiparkinson agents**; levodopa; interactions, tests, laboratory, phosphotungstate uric acid, discussion, 1458
- Ascorbic acid**
- effects; lack, urinary pH, spinal cord injury and neurogenic bladder patients, 235
- interactions; tests, laboratory, phosphotungstate uric acid, discussion, 1458
- ASHP**, see American Society of Hospital Pharmacists
- ASHP Affiliates**, 12, 153, 329, 454, 613, 764, 913, 1043, 1172, 1286, 1452, 1605
- Alabama Society of Hospital Pharmacists, 12, 913, 1043, 1452
- Arizona State Council of Hospital Pharmacists, 12, 153, 1605
- California Society of Hospital Pharmacists, 12, 454, 613, 1286, 1452, 1605
- Connecticut Society of Hospital Pharmacists, 454, 613, 913
- District of Columbia Society of Hospital Pharmacists, 12, 913, 1605
- Florida Society of Hospital Pharmacists, 12, 153, 454, 764
- Georgia Society of Hospital Pharmacists, 1605
- Idaho Society of Hospital Pharmacists, 1605
- Illinois Council of Hospital Pharmacists, 1286, 1606
- Indiana Society of Hospital Pharmacists, 153, 329, 1172, 1606
- Iowa Society of Hospital Pharmacists, 613
- Kansas Society of Hospital Pharmacists, 614, 764
- Kentucky Society of Hospital Pharmacists, 14, 1286
- Louisiana Society of Hospital Pharmacists, 764, 1286
- Maine Society of Hospital Pharmacists, 1452
- Maryland Society of Hospital Pharmacists, 329, 1043, 1172, 1452
- Massachusetts Society of Hospital Pharmacists, 1452
- Michigan Society of Hospital Pharmacists, 1043
- Missouri Society of Hospital Pharmacists, 764
- Minnesota Society of Hospital Pharmacists, 764
- Montana Society of Hospital Pharmacists, 1452
- Nebraska Society of Hospital Pharmacists, 153, 1043, 1286
- New Jersey Society of Hospital Pharmacists, 153, 1044, 1452
- New York State Council of Hospital Pharmacists, 14, 153, 614, 913, 1286
- North Carolina Society of Hospital Pharmacists, 614
- Ohio Society of Hospital Pharmacists, 1044, 1606
- Oklahoma Society of Hospital Pharmacists, 153, 329, 614, 1044
- Oregon Society of Hospital Pharmacists, 454, 614, 1045
- Pennsylvania Society of Hospital Pharmacists, 454
- Rhode Island Society of Hospital Pharmacists, 616, 1452
- South Carolina Society of Hospital Pharmacists, 1452
- Texas Society of Hospital Pharmacists, 764, 1172
- Utah Society of Hospital Pharmacists, 454, 1045
- Virginia Society of Hospital Pharmacists, 709, 1045, 1457
- Washington State Society of Hospital Pharmacists, 14, 616, 1045, 1172, 1286
- Wisconsin Society of Hospital Pharmacists, 454
- Aspirin**; interactions; tests, laboratory, phosphotungstate uric acid, discussion, 1458; ticrynafen, lack, effects, uric acid level, patient, 334
- Asthma**; epinephrine hydrochloride; acute, dosage, patients, 1326
- Automation, data processing**
- calculators; aminoglycosides, antibiotics, dosage schedules and blood levels, 225; programmable, prediction, phenytoin dosage schedules, 529
- Automation, data processing, computers**
- dosage schedules; antibiotics, and anti-infective agents, meningitis or bacteremia patients, 523; pharmacokinetics, blood levels vs time profiles, 1631
- drug interactions; geriatrics, monitoring, patient profile, 385
- parenteral nutrition; formulations, calculation, 22
- ticrynafen; drug information, hospital pharmacy, formulary and recall, 1305
- Azathioprine**; colitis, ulcerative; therapy, review, 1635

## B

- Baclofen**; dipropionate; rhinitis, vasomotor; therapy, discussion, 1496
- Benzodiazepines**; package inserts; patients, pharmacists, hospital, legal implications, 1656
- Bleeding**; phenytoin sodium; proteins, plasma, patients, 232
- Bleomycin sulfate**; injections; intravenous, stability, lack, effects, cellulose ester membrane filters, 935
- Blood**; effects; insulin, adsorption, containers, i.v., glass and plastics, 1323
- Blood levels**
- amikacin; morbidly obese patients, 519
- aminoglycosides; antibiotics, calculators, 225
- antibiotics; dosage schedules, computers, meningitis or bacteremia patients, 523
- anticonvulsants; therapy, forms, inpatients, 772
- anti-infective agents; dosage schedules, computers, meningitis or bacteremia patients, 523
- chloramphenicol sodium succinate; dialysis, hemo-, effects, patients, 1083
- cimetidine; relation, lack, gastric acidity, ulcer patients, 375
- digoxin; analysis, rational therapy, hospitals, 1466; increased, interactions, apironolactone, radioimmunoassay, cirrhotic patients, 1518
- drugs; analysis, and costs, role, clinical pharmacists, 61
- gentamicin; effects, creatinine clearance, patients, 1489; errors, variable results, radioimmunoassay and enzyme multiplied immunoassay, 1049; pharmacokinetics, models, hemodialysis patients, 1077
- lithium; relation, saliva levels, manic depressive patients, 514
- lithium carbonate; capsules, humans, 1528; lack, effects, leukocytosis, patients, 1525
- mefenamic acid; lack, effects, hemodialysis, patients, 956
- phenytoin; calculators, programmable, prediction, 529; dosage schedules, computers, models, vs time profiles, patients, 1631; dosage schedules, methodology, 128
- phenytoin sodium; dosage, single, oral, patients, 232
- theophylline; dosage schedules, computers, models, vs time profiles, patients, 1631; equivalency, following aminophylline tablets, patients, 1618; lack, effects, phosphotungstate uric acid test, patients, 1522
- tobramycin; analysis, effects, carbenicillin, patient, 702

**Book Reviews**, 122, 280, 574, 724, 1249; 1412, 1556, 1686

*Advances in Medical Oncology, Research and Education: Volume II, Cancer Control*, 1412

*Advances in Pharmacology and Therapeutics: Volume*

- 6, Clinical Pharmacology*, 280
- AMA Drug Evaluations, Fourth Edition*, 1412
- The Anticancer Drugs*, 280
- Applied Therapeutics for Clinical Pharmacists, Second Edition*, 1249
- Clinical Cardiology, 2nd Edition*, 1416
- Clinical Laboratory Statistics, Second Edition*, 280
- Clinical Pharmacy and Therapeutics*, 1558
- Drug Interactions, Fourth Edition*, 281
- Drug Monitoring: A Requirement for Responsible Drug Use*, 282
- Drug Therapy Reviews, Volume 2*, 1560
- Enteral Hyperalimentation with Chemically Defined Elemental Diets: A Source Book, Second Edition*, 283
- The Family Prescription & Medication Guide*, 1416
- Financing of Health Care*, 1686
- Forensic Toxicology: Controlled Substances and Dangerous Drugs*, 283
- Giving Medications Correctly and Safely—Revised Edition*, 284
- Handbook of Drug Therapy*, 284
- Handbook of Emergency Drugs*, 122
- Handbook of Institutional Pharmacy Practice*, 724
- Handbook of Nonprescription Drugs, Sixth Edition*, 284
- Handbook of Poisoning, Tenth Edition*, 1687
- Handbook of Psychopharmacology, Volume 12, Drugs of Abuse*, 291
- Handbook on Injectable Drugs, Second Edition*, 1251
- Helping the Troubled Employee*, 574
- Human Aspects of Hospital Pharmacy Management, Three Vignettes, Volume 1*, 292
- Index Guide to Drug Information Retrieval*, 1686
- Measurement of Levels of Health*, 574
- Medical Pharmacology: Principles and Concepts, Ninth Edition*, 295
- Medication Teaching Manual: A Guide for Patient Counseling, 2nd Edition*, 1251
- Modern Drug Encyclopedia and Therapeutics Index, 15th Edition*, 574
- Modern IV Practices*, 1562
- Modern Pharmacistics*, 1688
- National Drug Policies*, 1688
- Nurse's Guide to Drugs*, 1418
- Oncology Pharmacy Practice: Proceedings of the American Society of Hospital Pharmacists' Institute*, 1418
- Parenteral & Enteral Nutrition: A Practical Guide*, 1693
- Patient Education in the Primary Care Setting: Proceedings of the Second Conference held in Madison Wisconsin, April 11-12, 1978*, 1693
- The Pharmaceutical Codex, Eleventh Edition*, 1693
- Pharmacy Technician Training Manual*, 1562
- Practical Drug Therapy*, 579
- Problems in Pediatric Drug Therapy*, 1698
- Radiopharmaceuticals II: Proceedings and International Symposium on Radiopharmaceuticals, March 19-22, 1979, Seattle, Washington*, 1698
- The Road to Recovery—Heart*, 579
- Self Assessment of Current Knowledge in Clinical Pharmacy, Second Edition*, 296
- Side Effects of Drugs: Annual 4, 1990*, 1698
- Sourcebook on Clinical Pharmacy*, 1562
- A Study Guide to Epidemiology and Biostatistics*, 587
- Technology in Hospitals—Medical Advances and Their Diffusion*, 296
- Books Received**, 125, 296, 425, 724, 880, 1131, 1252, 1421, 1564, 1700
- Brethium tosylate**; incompatibilities; additives, injections, glass and plastic containers, 803
- Bronchodilators**; isotharine; solutions, inhalation, stability, room temperature, following repackaging, 680
- Buyers Guide**, 1717

## C

- Calcium chloride**; incompatibilities; dobutamine hydrochloride, visual, 460; sodium phosphate, FreAmine II solutions, 673
- Calcium gluconate**
- incompatibilities; calcium phosphate, FreAmine II solutions, 673; dobutamine hydrochloride, visual, 460
- injections; stabilizers, edetate disodium, possible incompatibilities, additives, discussion, 174
- parenteral nutrition; interactions, edetate disodium stabilizer and trace elements, formulations, patients, 1474
- Calculators**
- aminoglycosides; antibiotics, dosage schedules and blood levels, 225
- phenytoin; dosage schedules, and blood levels, programmable, prediction, 529
- Canada**; hospital pharmacy; discussion, 501
- Capsules**; lithium carbonate; equivalency, generic, availability, humans, 1528
- Carbamazepine**; adverse reactions; leukocytosis, patient,

550

**Carbenicillin**

concomitant therapy; infections, functioning ventriculoperitoneal shunt, child, 268  
interactions; tobramycin, effects, blood level, analysis, patient, 702

**Cardiac drugs**

digoxin; infections, stability, effects, cellulose ester membrane filters, 935  
digoxin; blood levels, analysis, rational therapy, hospitals, 1466; package inserts, patients, pharmacists, hospital, legal implications, 1656; interactions, spironolactone, digoxin blood levels increased, radioimmunoassay, cirrhotic patients, 1518  
dobutamine hydrochloride; incompatibilities, additives, visual, 460  
procainamide; stability, additives, injections, water and dextrose, combination, sodium chloride, 1050

**Carisoprodol**

skeletal muscle relaxants; review, 1313

**Carmustine**

incompatibilities; sodium chloride or dextrose, alone and with sodium bicarbonate, room temperature, 877

**Cefamandole**

stability, temperature, freezing, repackaged in disposable syringes, 1087

**Cefamandole nafate**

injections; stability, chemical, microbiological and visual, 98

stability; effects, light and reconstitution, 334

**Cefazolin**

alone and with lidocaine; stability, temperature, freezing, repackaged in disposable syringes, 1087

**Cefazolin sodium**

admixtures; stability, thawing, microwave radiation, 211

toxicity; seizures, high CSF levels, renal failure patients, 271

**Cefoperazone**

interactions; alcohols, ethyl, facial flushing, tachycardia, diaphoresis, patients, 858

**Cellophane**

packaging; tablets, aminophylline, unit dose, stability, 1046

**Cephalexin**

concomitant therapy; effects, creatinine clearance following gentamicin, patients, 1489

stability; temperature, freezing, repackaged in disposable syringes, 1087

**Cephalexin sodium**

adverse reactions; precipitation, urinary, patient, 775

injections; intravenous, piggyback, equipment, costs, preparation, hospital pharmacy, 1342

**Cerebrospinal fluid levels**

cefazolin sodium; high, seizures, renal failure patients, 271

gentamicin; infections, functioning ventriculoperitoneal shunt, therapy, child, 268

**Charcoal activated**

formulations; taste, comparison, saccharin, sucrose, sorbitol, 237

**Chelating agents**

edetate disodium; incompatibilities, additives, injections, possible, discussion, 174; interactions, elements, trace, anesthesia, parenteral nutrition patient, 1474

**Chloramphenicol**

concomitant therapy; infections, functioning ventriculoperitoneal shunt, child, 268

**Chloramphenicol sodium succinate**

body distribution; dialysis, hemo-, effects, patients, 1083

**Chlorphenesin carbamate**

skeletal muscle relaxants; review, 1313

**Chlorpromazine**

combination, meprobamate, promethazine; comparison, thioriental, sedatives, pediatrics, computerized tomography, 222

**Chlorzoxazone**

skeletal muscle relaxants; review, 1313

**Chromatography, liquid**

theophylline; blood levels, following aminophylline tablets, patients, 1618

tolbutamide; tablets, equivalency, generic, 1329

**Chronopharmacology**

therapy; effects, discussion, 101

**Chromotherapy**

drug; effects, discussion, 101

**Cimetidine**

blood levels; relation, lack, gastric acidity, ulcer patients, 375

package inserts; patients, pharmacists, hospital, legal implications, 1656

rational therapy; inpatients, 1462

toxicity; psychoses, patient, 1667

ulcers; stress, therapy, review, 1651

**Cimetidine hydrochloride**

additives; injections, stability, visual and chemical, 390

**Circadian rhythm**

chronopharmacology; therapy, effects, discussion, 101

**Classified Advertising**

133, 299, 428, 588, 735, 884, 1017, 1136, 1254, 1425, 1674, 1701

**Clinical Case Reports**

268, 271, 550, 702, 858, 1105, 1551, 1667

**Clinical pharmacists**

literature; bibliographies, cardiology, endocrinology, and gastroenterology, 406

role; blood levels, drugs, analysis, and costs, 61; hospitals, future, discussion, 481; rational therapy, ambulatory clinic patients, comparison, physician assessments, 824;

views, FDA Commissioner, 886

role consultation; pharmacokinetics consultation service, hospitals, 1466

skilled nursing facilities; pharmaceutical services, contractual effects, rational therapy, 820

**Clinical pharmacy**

services; ambulatory care, clinics, pediatrics, 1339;

Canada, lack, discussion, 501; costs, research design, problems, 1290; effects, rational therapy, anti-infective agents and antibiotics, hospitals, 829; hospitals, future, discussion, 481; shared, three hospitals, 1306; workload, methodology, 53

**Clinical studies**

chronopharmacology; effects, discussion, 101

minoxidil; review, 808

**Clinistix**

interactions; methyldopa, lack, patients, 683

**Clinistix**

diagnostic agents; relation, glucose blood levels, critically ill patients, 950

interactions; methyldopa, lack, patients, 683

**Clofibrate**

package inserts; patients, pharmacists, hospital, legal implications, 1656

**Coal tar**

topical therapy; psoriasis, review, 814

**Communications**

pharmacists, hospital; effects, primary nursing, 1093

**Community service**

drug information centers; consumers, and health professionals, 1215; university, consumers, description, 1206

drug information systems; statewide, decentralized, consumers, description, 1211

pharmacists, hospital; rehabilitation, vocational, role, 1178

poisoning; control, kits, maternity discharge patients, 789

**Competency**

pharmacists; education, patients, anticoagulants, programs, 89

**Concentration**

diuretics; administration sets, 1176;

injections, effects, containers and administration sets, availability and stability, 436; injections, i.v., effects, containers and administration sets, 492

**Consumers**

drug information; consultation, pharmacists, service, 1176; systems, statewide, pharmacists, role, 1211

drug information centers; services, 1215; university, description, 1206

**Containers**

glass; adsorption, insulin, effects, blood, 1323; amber, effects, stability, fluorouracil solutions, 164; incompatibilities, nitroglycerin, additives, 618; lack, effects, bretylium tosylate incompatibilities, additives, 803; lack, effects, incompatibilities, verapamil hydrochloride and additives, 676; nitroglycerin, injections, i.v., stability, effects, 201; stability, cefamandole nafate injections, 98

glass, comparison, plastic; diazepam, injections, effects, availability and stability, 496

glass, comparison, polyvinyl chloride; diazepam, injections, i.v., effects, stability, 492

hypotensive agents; effects, compliance, patients, 379

plastics; incompatibilities, Amin-Aid, disintegration, 464; lack, effects, bretylium tosylate incompatibilities, additives, 803; nitroglycerin, injections, i.v., stability, effects, 201

plastics, comparison, glass; diazepam, injections, effects, availability and stability, 496

polyolefin; incompatibilities, nitroglycerin, additives, 618; lack, effects, incompatibilities, verapamil hydrochloride and additives, 676

polyvinyl chloride; cefazolin sodium, admixtures, stability, thawing, microwave radiation, 211; incompatibilities, nitroglycerin, additives, 618; lack, effects, incompatibilities, verapamil hydrochloride and additives, 676; mixing, additives, methods, 1610; stability, cefamandole nafate injections, 98

polyvinyl chloride, comparison, glass; diazepam, injections, i.v., effects, stability, 492

**Contamination**

admixtures; injections, i.v., control, quality, forms, 189

injections; vials, multiple dose, lack, guidelines, 1610

microbiological; additives, injections, control, quality, aseptic operator technique, 668; cefamandole nafate, injections, glass and polyvinyl chloride containers, 98

Content uniformity; tolbutamide; tablets, equivalency, generic, 1329

**Contraindications**

cefazolin sodium; seizures, high CSF levels, renal failure patients, 271

minoxidil; review, 808

vasoconstricting agents; rebound congestion, vasomotor, rhinitis, therapy, discussion, 1496

**Control, quality**

additives; injections, cumulative sum control charts, 655;

injections, i.v., guidelines, quality assurance, centralized hospital services, 645; injections, microbiological contamination, aseptic operator technique, 668

admixtures; injections, i.v., visual inspection and environmental testing, 189

Control, quality, see also Quality assurance

Controlled substances; hospital pharmacy; monitoring, system, based upon Controlled Substances Act, 1296

Correction Notices, 180, 476, 637, 794, 1052, 1482, 1625

ASHP Affiliates (Sep 1980), 1625

Comparison of computer-assisted medical record audit with other drug use review methods (Dec 1979), 1052

Data collection techniques: observation (Sep 1980), 1625

Determining aminoglycoside dosage and blood levels using a programmable calculator (Feb 1980), 794

Effect of quinine on serum digoxin concentrations (Jul 1979), 180

Improving medication compliance by counseling and special prescription container (Mar 1980), 1482

Medications not to be refrigerated (Nov 1979), 476

Phenytoin toxicity and blood levels after a large oral dose (Feb 1980), 637

Recommendations to pharmacists for solving problems with large-volume parenterals—1979 (May 1980), 1482

Serum theophylline levels in asthmatic children receiving sustained-release theophylline tablets (Dec 1979), 794

**Costs**

blood levels; drugs, analysis, role, clinical pharmacists, 61

cephalothin sodium; injections, i.v., piggyback, preparation, hospital pharmacy, 1342

clinical pharmacy; services, research design, problems, 1290

drugs; hospital pharmacy, indexes, 837; long-term care facilities, effects, centralized pharmacy services, 92; returns, long-term care facilities, comparison, unit dose and traditional, 1531

health care; Louisiana, effects, Medicaid formularies, 1350

package inserts; patients, law, FDA, pharmacists, hospital, 1656

pharmaceutical services; shared, hospitals, small rural, 1534

pharmacokinetics; consultation, service, clinical pharmacists, hospital, 1466

Creatinine; excretion; pediatrics, comparison, methods, 1514

**Cromolyn sodium**

colitis, ulcerative; therapy, review, 1635

rhinitis, vasomotor; therapy, discussion, 1496

**Crystallization**

mannitol; solutions, stability, temperature, storage kettle, 16

**Cupric sulfate**

incompatibilities; lack, parenteral nutrition, formulations, 1620

**Current Literature**

115, 277, 417, 564, 720, 866, 1006, 1121, 1246, 1400, 1553, 1682

**Cyanocobalamin**

injections; intravenous, stability, lack, effects, cellulose ester membrane filters, 935

**Cyclobenzaprine hydrochloride**

skeletal muscle relaxants; review, 1313

**D**

Data collection; methodology; observation, techniques, 1235; techniques, mail questionnaire, 1113

Degrees; education, pharmaceutical; predictions, 21st century, discussion, 355

Denatonium benzoate; combination, acetone, alcohol, ethyl, isopropylacetone; incompatibilities, povidone-iodine, loss of free iodine, 464

Dependence; drugs; pharmacists, role, ambulatory care, pediatric clinic, 1339

**Dextrose**

additives; cimetidine hydrochloride, stability, visual and chemical, 390; diazepam, injections, 496; diazepam, injections, i.v., 492; effects, stability, i.v., phenytoin sodium, 95; injections, stability, effects, cellulose ester membrane filters, 935; nitroglycerin, incompatibilities, containers, polyvinyl chloride, polyolefin, glass, 618

admixtures; cefazolin sodium, stability, thawing, microwave radiation, 211

alone and with sodium bicarbonate; incompatibilities, carmustine, room temperature, 677

combination, sodium chloride; additives, effects, procainamide, stability, 1050

diluents; cefamandole nafate, injections, effects, stability, 98

effects; incompatibilities, sodium phosphate and calcium chloride or calcium gluconate, FreAmine II solutions, 673

incompatibilities; verapamil hydrochloride, additives, injections, 676

injections; intravenous, drop size, effects, administration sets, 1346

parenteral nutrition; toxicity, blood coagulation, due to inline filter, patients, 1616

**Diagnostic agents**

Clinistix; relation, glucose blood levels, critically ill pa-



- lients, 950  
metrizamide; drug interactions, toxicity, pharmacology, review, 510
- Dialysis:** hemo-; effects, chloramphenicol sodium succinate, body distribution, patients, 1083; gentamicin, blood levels, pharmacokinetics, models, patients, 1077; lack, effects, mefenamic acid blood levels, patients, 956
- Diazepam:** administration sets; effects, concentration and flow rate, 1176  
injections; availability, and stability, effects, containers and administration sets, 496; intravenous stability, effects, containers and administration sets, 492  
patient information; labeling, tests, readability, evaluations, 1504  
skeletal muscle relaxants; review, 1313
- Digoxin:** injections; intravenous, stability, effects, cellulose ester membrane filters, 935
- Digoxin:** blood levels; analysis, rational therapy, hospitals, 1466  
interactions; spironolactone, digoxin blood levels, increased radioimmunoassay, cirrhotic patients, 1518  
package inserts; patients, pharmacists, hospital, legal implications, 1656
- Dilants:** alcohol, benzyl; iron dextran, formulations, 206  
dextrose; cefamandole nafate, injections, effects, stability, 98  
sodium chloride; cefamandole nafate, injections, effects, stability, 98  
water; cefamandole nafate, injections, effects, stability, 98
- Disintegration:** tolbutamide; tablets, equivalency, generic, 1329
- Dissociation constants:** phenytoin; effects, solubility, additive, large volume parenterals, 1647
- Dissolution:** fluorouracil; precipitates, injections, lack, effects, microwave radiation, on stability, 678
- Dissolution rates:** tolbutamide; tablets, equivalency, generic, 1329
- Diuretics:** furosemide; therapy, effects, creatinine clearance following gentamicin, patients, 1489  
mannitol; incompatibilities, brylition tosylate, effects, cold temperatures, 803  
spironolactone; interactions, digoxin, increased blood levels, radioimmunoassay, cirrhotic patients, 1518  
ticrynafin; drug information, computers, hospital pharmacy, formulary and recall, 1305
- Debutamine hydrochloride:** incompatibilities; additives, injections, visual, 460
- Doseage:** anticonvulsants; forms, mental retardation facilities, inpatients, 772; therapy, forms, inpatients, 772  
ascorbic acid; lack, effects, urinary pH, spinal cord injury and neurogenic bladder patients, 235  
cefazolin sodium; seizures, high CSF levels, renal failure patients, 271  
cimetidine; rational therapy, inpatients, 1462  
digoxin; blood levels, analysis, hospitals, 1466  
drugs; injections, i.v., administration sets, effects, drop size, 1346; equations, injections, micrograms, computation, 1304  
ephedrine hydrochloride; asthma, acute, patients, 1338  
gentamicin; high, intraventricular, infections, functioning ventriculoperitoneal shunt, therapy, child, 268; pharmacokinetics, models, hemodialysis patients, 1077  
lithium carbonate; lack, effects, leukocytosis, patients, 1525; toxicity, neutropenia, cancer patients, 1066  
mefenamic acid; lack, effects, hemodialysis, patients, 956  
minoxidil; review, 806  
phenytoin sodium; single, oral, pharmacokinetics and side effects, patients, 232
- Doseage forms:** stability; solids, following unit dose repackaging in hospital pharmacy, shelf conditions, 185
- Doseage schedules:** aminoglycosides; antibiotics, calculators, 225  
antibiotics; computers, pharmacokinetics, meningitis or bacteremia patients, 523; pharmacokinetics, methodology, 1356  
anti-infective agents; computers, pharmacokinetics, meningitis or bacteremia patients, 523  
chronopharmacology; effects, discussion, 101  
geriatrics; pharmacokinetics, review, 559  
pharmacokinetics; computers, models, blood levels vs time profiles, 1631  
phenytoin; calculators, programmable, prediction, 529; methodology, pharmacokinetics, 128  
theophylline; intravenous, toxicity, discussion, 49
- Doxepin:** adverse reactions; glossitis, patient, 1551
- Doxycycline:** interactions; warfarin, increased coagulation, patient, 1620
- Drops:** injections; intravenous, size, effects, administration sets, 1346
- Drug administration:** diazepam; administration sets, effects, concentration and flow rates, 1176  
injections; intravenous, administration sets, effects, drop size, 1346  
self-medication; containers, hypotensive agents, effects, compliance, clinic patients, 379
- Drug administration routes:** chlorpromazine, combination, meperidine, promethazine; intramuscular, sedatives, pediatrics, computerized tomography, 222  
gentamicin; intraventricular, high dosage, functioning ventriculoperitoneal shunt, infection, therapy, child, 268  
lidocaine; iontophoresis, comparison, swabbing, SC, patients, 843  
nutrition; enteral, comparison, parenteral, patients, 65  
thiopental; rectal comparison i.m., chlorpromazine, combination, meperidine, promethazine, sedatives, pediatrics, computerized tomography, 222
- Drug distribution systems:** hospitals; decentralized, pharmacy service unit; 78  
unit dose; audits, hospital pharmacy, 85; effects, sex, drug returns, long-term care facilities, comparison, traditional system, 1531; long-term care facilities, effects, centralized pharmaceutical services, 92; nystatin, suspensions, need, institutions, survey, 780
- Drug information:** adverse reactions; physicians, attitudes, pharmacist consultation, 243  
ambulatory care; clinics, pediatrics, pharmacists, role, 1339  
consumers; consultation, pharmacists, service, 1176  
forms; pharmacists, hospital, use in therapy assessment, 1616  
literature; patients, consultation, evaluation, 1509  
medicine; literature, bibliographies, cardiology, endocrinology, and gastroenterology, clinical pharmacists, 406  
pharmacists; hospitals, and community, sources, survey, Michigan, 687; role consultant, models, prediction of physician use, 483  
systems; states, pharmacists, role, consumers and health professionals, 1211  
ticrynafin; computers, hospital pharmacy, formulary and recall, 1305  
warfarin sodium; patients, reading levels, effects, comprehension and attitude, 240
- Drug information centers:** consumers; university, description, 1206  
evaluations; users, postcard questionnaire, 1614  
services; consumers, and health professionals, 1215
- Drug interactions:** acetaminophen and tests, laboratory; phosphotungstate uric acid, discussion, 1458  
alcohol, ethyl and cefoperazone; adverse reactions, facial flushing, tachycardia, diaphoresis, patient, 858  
aminophylline and tests, laboratory; lack, effects, phosphotungstate uric acid, patients, 1522  
anticoagulants; education, patients, programs, by pharmacists, audit, 89  
anticonvulsants; forms, mental retardation facilities, inpatients, 772  
antineoplastic agents and lithium carbonate; neutropenia, cancer patients, 1066  
ascorbic acid and tests, laboratory; phosphotungstate uric acid, discussion, 1458  
aspirin and tests, laboratory; phosphotungstate uric acid, discussion, 1458  
aspirin and ticrynafin; lack, effects, uric acid level, patient, 334  
calcium gluconate and parenteral nutrition; paresthesia, edetate disodium stabilizer and trace elements in formulation, 1474  
carbenicillin and tobramycin; blood levels, tobramycin, effects, analysis, patient, 702  
cefoperazone and alcohol, ethyl; adverse reactions, facial flushing, tachycardia, diaphoresis, patient, 858  
cephalothin and furosemide; effects, creatinine, patients, 1489  
cephalothin and gentamicin; effects, creatinine clearance, patients, 1489  
digoxin and spironolactone; increased, digoxin blood levels, radioimmunoassay, cirrhotic patients, 1518  
doxycycline and warfarin; coagulation, increased, patient, 1620  
edetate disodium and elements, trace; paresthesia, due to stabilizer in calcium gluconate, parenteral nutrition patient, 1474  
elements, trace and edetate disodium; paresthesia, due to stabilizer in calcium gluconate, parenteral nutrition, 1474  
food; health, possible, discussion, 789  
gentamicin and cephalothin; effects, creatinine clearance, patients, 1489  
gentamicin and furosemide; effects, creatinine clearance, patients, 1489  
geriatrics; computers, monitoring, patient profile, 385  
levodopa and tests, laboratory; phosphotungstate uric acid, discussion, 1458  
lithium carbonate and antineoplastic agents, neutropenia, cancer patients, 1066  
methyldopa and tests, laboratory; lack, effects, Clinistest, Tes-Tape and Clinistix, patients, 683  
metrizamide; review, 510  
minoxidil; review, 806  
parenteral nutrition and calcium gluconate; paresthesia, edetate disodium stabilizer and trace elements in formulation, 1474  
phenacetin and tests, laboratory; phosphotungstate uric acid, discussion, 1458  
spironolactone and digoxin; increased, digoxin blood levels, radioimmunoassay, cirrhotic patients, 1518  
tests, laboratory; interference, determinations, 12-channel autoanalyzer, 1333; phosphotungstate uric acid, discussion, 1458  
tests, laboratory and aminophylline; lack, effects, phosphotungstate uric acid, patients, 1522  
tests, laboratory and methyldopa; lack, effects, Clinistest, Tes-Tape and Clinistix, patients, 683  
ticrynafin and aspirin; lack, effects, uric acid level, patient, 334  
tobramycin and carbenicillin; blood levels, tobramycin, effects, analysis, patient, 702  
warfarin and doxycycline; coagulation, increased, patient, 1620
- Drug Reaction Alerts:** 117, 278, 420, 568, 721, 874, 1007, 1122, 1246, 1400, 1553, 1682
- Drug Therapy Reviews:** 65, 365, 808, 942, 1061, 1199, 1313, 1496, 1651
- Drug use review:** antibiotics; hospitals, clinical pharmaceutical services, effects, rational therapy, 829  
anti-infective agents; hospitals, clinical pharmaceutical services, effects, rational therapy, 829  
cimetidine; rational therapy, inpatients, 1462  
long-term care facilities; effects, centralized pharmaceutical services, drug consumption and costs, 92  
skilled nursing facilities; clinical pharmacists, contractual, effects, rational therapy, 820
- Drug utilization review, see Drug use review**
- Drugs:** recalls; industry, pharmaceutical, procedures, discussion, 1305  
returns; long-term care facilities, comparison, unit dose and traditional system, 1531  
unapproved use, views, FDA Commissioner, 738
- Drugs, adverse reactions:** alcohol, ethyl; interactions, cefoperazone, facial flushing, tachycardia, diaphoresis, patient, 858  
anticonvulsants; forms, mental retardation facilities, inpatients, 772  
carbamazepine; leukocytosis, patient, 550  
cefoperazone; interactions, alcohol, ethyl, facial flushing, tachycardia, diaphoresis, patient, 858  
cephalothin sodium; urinary, precipitation, patient, 775  
doxepin; glossitis, patient, 1551  
erythromycin; and salts, review, 1199  
minoxidil; review, 806  
pharmacists; consultations, physicians attitudes, 243
- Drugs, availability:** aminophylline; tablets, patients, 1618  
anticonvulsants; forms, mental retardation facilities, inpatients, 772  
diazepam; injections, effects, containers and administration sets, 496; injections, i.v., effects, containers and administration sets, 492  
erythromycin; and salts, review, 1199  
lithium carbonate; capsules, humans, 1528
- Drugs, body distribution:** amikacin; morbidly obese patients, 519  
chloramphenicol sodium succinate; dialysis, hemo-, effects, patients, 1083  
chronopharmacology; effects, discussion, 101
- Drugs, clinical effectiveness:** erythromycin; and salts, review, 1199  
prescriptions; pharmacy, community, statistics, 833
- Drugs, over-the-counter use review:** long-term care facilities, effects, centralized pharmaceutical services, drug consumption and costs, 92

## E

## Economics

- hospital pharmacy; Canada, discussion, 501  
National Coordinating Committee on Large Volume Parenterals; funding views, FDA Commissioner, 738
- Edetate disodium:** incompatibilities; additives, injections, possible, discussion, 174  
interactions; elements, trace, paresthesia, parenteral nutrition patient, 1474
- Editorials:** 49, 187, 353, 481, 641, 801, 933, 1059, 1195, 1311, 1487, 1629  
ASHP and residency training, 1196  
Drug information for consumers, 1195  
Good work, NCCLP, 642  
Hospital-based care for ambulatory patients, 801  
Let's objectively evaluate clinical pharmacy, 933

A new direction for the '80s: The college of pharmacy and allied health professions, 187  
 Of technicians, job satisfaction, and job enrichment, 353  
 Poisoning patients with intravenous theophylline, 49  
 Priorities for hospital pharmacy in the 1980s, 481  
 Protecting our investment in sterile products, 1311  
 Thinking positive about PPIs, 1437  
 Those faking pharmacists, 641  
 Trends in *Journal* content, 1629  
 Volume 37, 50  
 Will a technician steal your job?, 1059

#### Education

ambulatory care; clinics, pediatrics, pharmacists, role, 1339  
 patients; anticoagulants, programs, by pharmacists, audit, 89  
 personnel, pharmacy; additives, injections, i.v., centralized hospital service, 645; additives, injections, control, quality, microbiological contamination, aseptic operator technique, 668 intravenous therapy, guidelines, Subcommittee on Dissemination of Results of the National Coordinating Committee on Large Volume Parenterals, 660

#### Education, pharmaceutical

Canada; effects, hospital pharmacy, discussion, 501  
 continuing; research, methodology, pharmacists, 107  
 curriculum; quality assurance, undergraduate, discussion, 922  
 drug information; systems, statewide, pharmacists, role, consumers and health professionals, 1211  
 history; 21st century, discussion, 355  
 personnel, pharmacy; supportive, formalization and training, discussion, 1300  
 residencies; hospitals, salaries and benefits, 1980 survey, 1392  
 technicians; hospitals, sterile products, standards, 1311

#### Electrolytes

dextrose; injections, i.v., effects, drop size, administration sets, 1346  
 sodium chloride; injections, i.v., effects, drop size, administration sets, 1346

Elements; trace; incompatibilities, parenteral nutrition, formulations, 1620; interactions, edetate disodium, parenteral nutrition patient, 1474  
 Emetics; ipecac; poisoning, control, kits, maternity discharge patients, 789

Epinephrine hydrochloride; dosage; asthma, acute, patients, 1326

#### Equations

dosage; drugs, injections, micrograms, computation, 1304  
 solubility; phenytoin, additives, large volume parenterals, 1647

#### Equipment

autoanalyzers; 12-channel, tests, laboratory, interactions, drugs, interference, determinations, 1333  
 injections; intravenous, guidelines, Subcommittee on Dissemination of Results of the National Coordinating Committee on Large Volume Parenterals, 660  
 injections; intravenous, piggyback, cephalothin sodium, preparation, hospital pharmacy, 1342  
 kettles; mannitol, solutions, stability, temperature, 16  
 manufacturing; antineoplastic agents, hospital pharmacy, 1184  
 nebulizers; drugs, stability, upon repackaging, 680

#### Equipment and Supplies

Abbott Laboratories, filter, 733; filter sets, 1569  
 Baxa Corporation, dispenser, 1569; filler, 1569  
 Burron Medical Products, Inc., filter needles, 1566; fluid dispensing system, 733  
 Cutter Laboratories, administration sets, 1566  
 Drustar, Inc., brochure, 734; drawers, 1572; packets, 1572; trays, 1572  
 Dycem Limited, wall-to-wall flooring, 1572  
 Equip Corporation, syringe and bottle destroyer, 733  
 Fanson Specialty Materials Division, labels, 733  
 GCA/Precision Scientific, refrigerator, 274  
 Gelman Sciences, Inc., catalog, 274; petri dish, 274  
 Health Care Logistics, cart, 1569; medication blisters, 1569  
 Healthmark Industries Co., closures, 1572; security storage unit, 733  
 Jenner International Distributors, Inc., security systems, 1569  
 Jewett Refrigerator Company, refrigerators, 274  
 Magenta Corporation, i.v. clamp, 274  
 Medi-Dose, Inc., Additive label, 1566  
 Millipore Corporation, particulate filter, 734  
 Parke-Davis, Division of Warner-Lambert Co., pharmacy fixtures, 733  
 Patient Prescription Information, Inc., prescription information, 274  
 Silver Industries, Inc., Dial-a-Dose, 733  
 United Hospital Supply Corp., cart, 1566; lateral sliding assembly, 1566  
 Vaponec, Inc., catalog, 274  
 Waterloo Industries, Inc., patient bin, 1569

Wheaton Scientific, dispenser, 734

#### Equivalency

erythromycin; and salts, review, 1199  
 injections; intravenous, administration sets, effects, drop size, 1346

#### Equivalency, generic

aminophylline; tablets, patients, 1618  
 drugs; nomenclature, tables, Great Britain and U.S., 624  
 lithium carbonate; capsules, humans, 1528  
 tolbutamide; tablets, dissolution characteristics, 1329  
 Ergonovine maleate; injections; intravenous, stability, lack, effects, cellulose ester membrane filters, 935  
 Ergot; preparations; migraine therapy, review, 365

#### Errors

diazepam; administration sets, effects, concentration and flow rates, 1176  
 digoxin; blood levels, analysis, hospitals, 1466  
 drug administration; injections, i.v. administration sets, effects, drop size, 1346  
 gentamicin; blood levels, variable results, radioimmunoassay and enzyme multiplied, immunoassay, 1049  
 injections; osmolality, and osmolarity, 504  
 tests, laboratory; anticonvulsants, forms, mental retardation facilities, inpatients, 772

#### Errors, medication

consumers; prevention, drug information centers, 1215; prevention, role, university drug information centers, 1208  
 omission; effects, compliance, patient consultation and containers, hypertension clinic, 379

Erythromycin; and salts; chemistry, availability, adverse reactions, review, 1199

#### Erythromycin estolate

chemistry; availability, adverse reactions, review, 1199  
 interactions; tests, laboratory, interference, 12-channel autoanalyzer, 1333

Erythromycin ethylsuccinate; chemistry; availability, adverse reactions, review, 1199

#### Erythromycin stearate; chemistry; availability, adverse reactions, review, 1199

#### Excretions

cephalothin sodium; urinary, precipitation, patient, 775  
 chloramphenicol sodium succinate; dialysis, hemo-, effects, total body clearance, patients, 1083  
 creatinine; pediatric, comparison, methods, 1514

## F

#### Filters

HEPA; antineoplastic agents, injections, manufacturing hospital pharmacy, 1184  
 inline; toxicity, blood coagulation, dextrose, parenteral nutrition, patients, 1616  
 membrane; inline, cellulose ester, additives, effects, stability, 935; nitroglycerin, injections, i.v., stability, effects, 201

Flow; rate; diazepam, administration sets, 1176

Flufenamic acid; migraine therapy, review, 365

Fluorides; combination, vitamins; formulations, pediatric, sweetening agents, 1048

#### Fluorouracil

injections; precipitates, dissolution, lack, effects, microwave radiation, on stability, 678  
 stability; solutions, amber glass containers, effects, temperature, pH, 164

Folic acid; injections; intravenous, stability, lack, effects, cellulose ester membrane filters, 935

Food; health; interactions, drugs, possible, discussion, 787

#### Food and Drug Administration

laws; package inserts, patients, history, 1660; package inserts, patients, pharmacists, hospital, 1656  
 marketing; drugs, laws, premarketing approval, Lannett and Pharmadyne decisions, 537  
 rational therapy; role, views, Commissioner, 886  
 regulations; package inserts, patients, pharmacists positive approach, 1487; vitamins, multiple, injections, formulations, 789

#### Forms

additives; injections, control, quality, cumulative sum control charts, 655  
 anticonvulsants; therapy, blood levels and dosage, inpatients, 772  
 control, quality; admixtures, injections, i.v., visual inspection and environmental testing, 189  
 drug information; pharmacists, hospital, use in therapy assessment, 1616  
 patient information; pharmacists, hospital, use in therapy assessment, 1616

#### Formulations

hospitals; ticrynafen, drug information, computers, 1302  
 Medicaid; Louisiana, critique, 1350

#### Formulations

charcoal activated; taste, comparison, saccharin, sucrose,

sorbitol, 237

fluorides, combination, vitamins; pediatric, sweetening agents, 1048

indium In-111 oxine; leukocytes, labeling, 848

iodine, combination, potassium iodide; solutions, 1048  
 iron dextran; stability, parenteral nutrient solutions, 206

parenteral nutrition; computers, calculation, 22; edetate disodium and elements, trace, paresthesia, patient, 1474; incompatibilities, trace elements, 1620  
 potassium iodide, combination, iodine; solutions, 1048  
 vitamins, combination, fluorides; pediatric, sweetening agents, 1046; multiple, injections, FDA, 789

FreAmine II; nutrition, parenteral; solutions, incompatibilities, sodium phosphate and calcium chloride or calcium gluconate, 673

Furosemide; therapy; effects, creatinine clearance following gentamicin, patients, 1489

## G

#### Gastrointestinal drugs

cimetidine; package inserts, patients, pharmacists, hospital, legal implications, 1656; rational therapy, inpatients, 1462; toxicity, psychoses, patient, 1667  
 colitis, ulcerative; therapy, review, 1635

#### Gentamicin

blood levels; errors, variable results, radioimmunoassay and enzyme multiplied immunoassay, 1049; pharmacokinetics, models, hemodialysis patients, 1077  
 dosage; high, intraventricular, infections, functioning ventriculoperitoneal shunt, therapy, child, 268  
 therapy; effects, creatinine clearance, patient variables, 1489

Gentamicin sulfate; concomitant therapy; renal failure patients, 271

#### Geriatrics

drug interactions; computers, monitoring, patient profile, 385

pharmacokinetics; dosage schedules, review, 559

Glass; containers; adsorption, insulin, effects, blood, 1323; amber, effects, stability, fluorouracil solutions, 164; diazepam, injections, effects, availability and stability, 496; diazepam, injections, i.v., effects, stability, 492; incompatibilities, nitroglycerin, additives, 618; lack, effects, beryllium tosylate incompatibilities, additives, 903; lack, effects, incompatibilities, verapamil hydrochloride and additives, 676; nitroglycerin, injections, i.v., stability, effects, 201; stability, cefamandole nafate injections, 96

Glucocorticoids; topical therapy; psoriasis, review, 814

#### Guidelines

additives; injections, i.v., quality assurance, centralized hospital services, 645

injections; intravenous, Subcommittee on Dissemination of Results of the National Coordinating Committee on Large Volume Parenterals, 660

National Coordinating Committee on Large Volume Parenterals; injections, i.v., hospital pharmacists, 663

## H

#### Half-life

gentamicin; pharmacokinetics, models, hemodialysis patients, 1077  
 mefenamic acid; lack, effects, hemodialysis, patients, 956

Haloperidol; solutions; oral, stability, room temperature, following repackaging, 680

Harvey A. K. Whitney Lecture Award; American Society of Hospital Pharmacists; 1979, 355

#### Health benefit programs

third party; Medicaid, formularies, Louisiana, critique, 1350  
 national health insurance; Canada, effects, hospital pharmacy, 501

#### Health care

Louisiana formularies, Medicaid, 1350  
 nursing, primary, delivery, models, 1089  
 pharmacists; role, view, FDA Commissioner, 886  
 planning; pharmacy role, Health Systems Agencies and State Health Planning and Development Agencies, 1072  
 services; Canada, effects, hospital pharmacy, 501

#### Health professions

drug information; systems, statewide, pharmacists, role, 1211

drug information centers; services 1215

Health Systems Agencies; pharmacists; role, 1072

Heparin; injections; intravenous, drop size, effects, administration sets, 1346; intravenous, stability, lack, effects, cellulose ester membrane filters, 935

#### History

hospital pharmacy; future, clinical services and technician use, 481

nursing; concepts, 1069  
 package inserts; patients, laws, FDA, 1660  
**Hospital pharmacy, see Pharmacy, institutional, hospital**  
**Hospitals**  
 history; 21st century, predictions, discussion, 355  
 nursing; primary, effects, pharmacy services, 1091; primary, effects, pharmacy services, 1093; primary, health care, delivery, models, 1089  
 personnel; pharmacy; supportive, technicians, job satisfaction, 359  
 pharmaceutical services; shared, small rural, 1534  
 pharmacokinetics; consultation, services, and costs, clinical pharmacists, 1466  
 standards; Joint Commission on Accreditation of Hospitals, effects, pharmaceutical services, 430

## Hours

personnel; drug information centers, services, consumers and health professionals, 1215  
 twenty-four hour service; hospital pharmacy, decentralized, team, pharmacy service unit, 78

## Hydrogen ion concentration

cefazolin sodium; admixtures, stability, thawing, microwave radiation, 211  
 cimetidine hydrochloride; additives, injections, stability, visual and chemical, 490  
 diazepam; injections, effects, containers and administration sets, availability and stability, 496  
 effects; cefamandole nafate, stability, glass and polyvinyl chloride containers, 98; lack, bretylium tosylate, incompatibilities, additives, glass and plastic containers, 803

fluorouracil; solutions, stability, amber glass containers, 164  
 nutrition, parenteral; amino acids, solutions, titration curves, 388

phenytoin; effects, solubility, additives, large volume parenterals, 1647

phenytoin sodium; effects, stability, i.v. additives, comparison, dextrose and sodium chloride, 95  
 procainamide; additives, injections, lack, effects, stability, 1060

## 5-Hydroxytryptophan; migraine therapy; review, 362

## Hyperalimentation, see Parenteral nutrition

## Hypertensive agents

bretylium tosylate; injections, stability, glass and plastic containers, 803  
 compliance; effects, patient consultation and containers, hypertension clinic, 379  
 methyldopa; interactions, lack, Clinintest, Tes-Tape and Clinintest, patients, 683  
 minoxidil; review, 808

## I

**Immunoassay**; enzyme multiplied, gentamicin, blood levels, comparison, radioimmunoassay, 1049

## Incompatibilities

additives and cimetidine hydrochloride; lack, 390  
 additives and dobutamine hydrochloride; visual, 460  
 additives and filters; membrane, cellulose ester, effects on stability, 935  
 additives and verapamil hydrochloride; lack, glass and plastic containers, 676

alanine; lack, parenteral nutrition, formulations, 1620; Amin-Aid and plastics; containers, disintegration, 464  
 aminoacetic acid; lack, parenteral nutrition, formulations, 1620;

blood and insulin; adsorption, insulin, containers, i.v., glass and plastics, 1323

bretylium tosylate; injections, additives, glass and plastic containers, 803

calcium chloride and sodium phosphate; FreAmine II solutions, 673

calcium gluconate and sodium phosphate; FreAmine II solutions, 673

carmustine and dextrose; alone and with sodium bicarbonate, room temperature, 677

carmustine and sodium chloride; alone and with sodium bicarbonate, room temperature, 677

cimetidine hydrochloride and additive; lack, 390  
 containers and nitroglycerin; additives, glass, polyvinyl chloride, polyolefin, 618

cupric sulfate; lack, parenteral nutrition, formulations, 1620

dextrose and carmustine; alone and with sodium bicarbonate, room temperature, 677

diazepam; injections, effects, containers and administration sets, 496; injections, i.v., effects, containers and administration sets, 492

dobutamine hydrochloride and additives; visual, 460  
 edetate disodium; additives, possible, discussion, 174  
 insulin and blood; adsorption, insulin, containers, i.v., glass and plastics, 1323

isopropyl acetone and povidone-iodine; loss, free iodine, 464

nitroglycerin and containers; additives, glass, polyvinyl chloride, polyolefin, 618

plastics and Amin-Aid; containers, disintegration, 464  
 povidone-iodine and acetone; loss, free iodine, 464

povidone-iodine and isopropyl acetate; loss, free iodine, 464

sodium chloride and carmustine; alone and with sodium bicarbonate, room temperature, 677

sodium phosphate and calcium chloride or calcium gluconate; FreAmine II solutions, 673

ticarcillin and tobramycin; stability, tobramycin, in vitro blood samples, 920

tobramycin and ticarcillin; stability, tobramycin, in vitro blood samples, 920

verapamil hydrochloride and additives; lack, glass and plastic containers, 676;

zinc chloride; parenteral nutrition, formulations, 1620  
 zinc sulfate, parenteral nutrition, formulations, 1620

**Indian Is-111 oxine; methodology, leukocytes, labeling, 847**

## Industry, pharmaceuticals

drugs; recalls, procedures, discussion, 1305  
 marketing; drugs, laws, premarketing approval, Lannett and Pharmadyne decisions, 537

## Injections

antineoplastic agents; manufacturing, hospital pharmacy, equipment, 1154

bretylium tosylate; intravenous, stability, additives, glass and plastic containers, 803

calcium gluconate; stabilizers, edetate disodium, possible incompatibilities, additives, discussion, 174

cefamandole nafate; stability, chemical, microbiological and visual, 98; stability, effects, light and reconstitution, 334

contamination; vials, multiple dose, contamination, lack, guidelines, 1610

diazepam; administration sets, effects, concentration and flow rates, 1176; availability, and stability, effects, containers and administration sets, 496; intravenous stability, effects, containers and administration sets, 492

drugs; dosage, equations, micrograms, computation, 1703

fluorouracil; precipitates, dissolution, lack, effects, microwave radiation, on stability, 678

intravenous; administration sets, effects, drop size, 1346; admixtures, quality control, visual inspection and environmental testing, 180; guidelines, Subcommittee on Dissemination of Results of the National Coordinating Committee on Large Volume Parenterals, 660; insulin, adsorption, containers, glass and plastics, effects, blood, 1323; nitroglycerin, stability, effects, filters, containers and administration sets, 201; sterility, technicians, hospital pharmacy, training and procedures, 1311

labeling; osmolality, and osmolality, 504  
 National Coordinating Committee on Large Volume Parenterals; guidelines, hospital pharmacists, 663

pentazocine hydrochloride; stability, room temperature, following repackaging, 680

promethazine hydrochloride; stability, room temperature, following repackaging, 680

reconstitution; cephalothin sodium intravenous, piggy-back, equipment, costs, preparation, hospital pharmacy, 1342

vitamins; multiple, formulations, FDA, 789

**Inspectors; hospital pharmacy; state boards, regulations, 592**

## Insulin

adsorption; containers, i.v., glass and plastics, effects, blood, 1323

injections; intravenous, stability, effects, cellulose ester membrane filter, 935

mechanism of action; antibodies, patients, 1105

**Intravenous therapy; guidelines; Subcommittee on Dissemination of Results of the National Coordinating Committee on Large Volume Parenterals, 660**

## Inventory

control; hospital pharmacy, indexes, 837  
 drugs; shared, hospitals, small rural, 1534

**Iodine**; combination, potassium iodide; solutions, formulations, 1048

**Ipecac**; poisoning; control, kits, maternity discharge patients, 789

**Iron dextran**; formulations; stability, parenteral nutrient solutions, 396

**Isoetharine**; solutions; inhalation, stability, room temperature, following repackaging, 680

**Isoethetene**; migraine therapy; review, 365

**Isopropyl acetone**, combination, acetone, alcohols, ethyl, isopropyl acetone; incompatibilities, povidone-iodine, loss of free iodine, 464

## J

**Joint Commission on Accreditation of Hospitals**; standards; hospitals, effects, pharmaceutical services, 430

**Journal References**, 115, 277, 417, 564, 720, 866, 1006, 1121, 1246, 1400, 1553, 1682

**Journals**; articles; system, filing, 718

## K

**Keratolytics**; topical therapy; psoriasis, review, 814

## L

## Labeling

antineoplastic agents; pharmacists, and nurses, role, hospitals, 1617

injections; osmolality, and osmolality, 504  
 patient information; diazepam, tests, readability, evaluations, 1509

**Labels**; parenteral nutrition; formulations, computer generated, 22

**Laboratories**; hospitals; role, clinical pharmacokinetic consultation service, 1466

**Law Notes**, 537, 1546, 1656

## Laws

cases; Lannett and Pharmadyne decisions, drugs, premarketing approval, 537

**Controlled Substances Act**; role, hospital pharmacy controlled substances monitoring system, 1296

package inserts; patients, history, FDA, 1660; patients FDA, pharmacists, hospital, 1656

## Legislation

American Society of Hospital Pharmacists, Legislative Alert System, pharmacists, participation, discussion, 160

pharmacists, institutional; negligence, determination professional standards of due care, 1546

**Legislative Alert System**; American Society of Hospital Pharmacists; pharmacists, hospital, participation, discussion, 160

**Letters**, 16, 160, 334, 460, 618, 772, 920, 1046, 1176, 1290, 1458, 1610

**Levodopa**; interactions; tests, laboratory, phosphotungstate uric acid, discussion, 1458

**Licensure**; hospital pharmacy; decentralized, state board regulations, 592

## Lidocaine

administration routes; iontophoresis, comparison, swabbing, SC, patients, 843

and cefazolin; stability, temperature, freezing, repackaged in disposable syringes, 1089

topical preparations; glossitis, therapy, doxepin-induced, patient, 1551

## Light

bretylium tosylate; effects, incompatibilities, injections, additives, glass and plastic containers, 803

effects; cefamandole nafate, stability upon reconstitution, 334

fluorouracil; solutions, effects, stability, 164

## Literature

clinical pharmacists, bibliographies, cardiology, endocrinology, and gastroenterology, 406

drug information; patients, consultation, evaluation, 1509; pharmacists, hospital and community, courses, survey, Michigan, 687

journals; articles, filing system, 618

**Lithium**; blood levels; relation, saliva levels, manic depressive patients, 514

**Lithium carbonate**  
 capsules; equivalency, generic, availability, humans, 1528

interactions; antineoplastic agents, neutropenia, cancer patients, 1066

toxicity; leukocytosis, patients, 1525

**Long-term care facilities**  
 drugs; returns, effects, unit dose, comparison, traditional system, 1531

pharmaceutical services; centralized, effects, drug consumption and costs, 92

**Louisiana**; formularies; Medicaid, critique, 1350

## M

**Magnesium sulfate**; incompatibilities; dobutamine hydrochloride, visual, 460

**Mannitol**  
 additives; incompatibilities, bretylium tosylate, effects, cold temperatures, 803

solutions; stability, temperature, storage kettle, 16

**Manpower**; hospital pharmacy; technicians, salaries, job satisfaction, 359

**Manufacturing**; antineoplastic agents; injections, hospital pharmacy, equipment, 1184

**Marketing**  
 drugs; laws, premarketing approval, Lannett and Pharmadyne decisions, 537; unapproved use, views, FDA



- Commissioner, 738  
postmarketing surveillance; views, FDA Commissioner, 886
- Mathematics**; costs; drugs, hospital pharmacy, use of indexes, 837
- Mechanism of action**  
carbenicillin and tobramycin; interactions, effects, tobramycin blood level, analysis, patient, 702  
doxepin; glossitis, patient, 1551  
insulin; antibodies, patients, 1105  
lithium carbonate; toxicity, neutropenia, cancer patients, 1066  
minoxidil; review, 808  
tobramycin and carbenicillin; interactions, effects, tobramycin blood level, analysis, patient, 702
- Medicine**; literature; clinical pharmacists, bibliographies, cardiology, endocrinology and gastroenterology, 406
- Meeting Dates**, 127
- Mefenamic acid**; blood levels; lack, effects, hemodialysis, patients, 956
- Meperidine**; combination, chlorpromazine, promethazine; comparison, thopental, sedatives, pediatrics, computerized tomography, 222
- Metabolism**; anticonvulsants; forms, mental retardation facilities, inpatients, 772
- Metaxalone**; skeletal muscle relaxants; review, 1313
- Methicillin**; concomitant therapy; infections, functioning ventriculoperitoneal shunt, child, 268
- Methocarbamol**; skeletal muscle relaxants; review, 1313
- Methodology**  
additives; injections, control, quality, microbiological contamination, aseptic operator technique, 688; injections, control, quality, sterility, cumulative sum control charts, 655  
antibiotics; dosage schedules, pharmacokinetics, 1356  
anticoagulants; education, patients, programs, by pharmacists, audit, 89  
anticonvulsants; forms, mental retardation facilities, inpatients, 772  
blood levels; drugs, analysis, role, clinical pharmacists, 61  
clinical studies; chronopharmacology, effects, discussion, 101  
Clinitest; relation, glucose blood levels, critically ill patients, 950  
computers; hospitals, ticrynafen, drug information, formulary and recall, 1305  
creatinine; excretion, pediatrics, 1514  
creatinine clearance; pediatrics, comparison, 195  
data collection; observation, techniques, 1235; techniques, mail questionnaire, 1113  
dosage schedules; antibiotics, and anti-infective agents, computers, pharmacokinetics, meningitis or bacteremia patients, 523; pharmacokinetics, computers, models, blood levels vs time profiles, 1631  
drug information centers; evaluations, users, postcard questionnaire, 1614  
drug interactions; geriatrics, computers, monitoring, patient profile, 385  
gentamicin; pharmacokinetics, blood levels, dosage, models, hemodialysis patients, 1077  
hospital pharmacy; workload, distributive and clinical services, 53  
lithium, saliva levels, estimation, blood levels, manic depressive patients, 514  
patient information; comprehension tests, reading levels, 215; labeling, diazepam, tests, readability, evaluations, 1594  
phenytoin; dosage schedules, calculators, programmable, prediction, 529; dosage schedules, pharmacokinetics, 138  
research; clinical pharmacy, services, design problems, costs, 1290; data, hypothesis testing, 1539; data, interpretation, 1394; data, statistics, interpretation, 1673; design, discussion, 398; designs, and models, discussion, 541; hypotheses, characteristics, 264; hypotheses, and questions, 267; nomenclature, reliability and validity of measures, 851; pharmacists, continuing education, 107; sampling techniques; 998; types, discussion, 694
- Methoxsalen**; package inserts; patients, pharmacists, hospital, legal implications, 1656
- Methyldopa**; interactions; tests, laboratory, lack, effects, Clinitest, Tes-Tape and Clinitest, patient, 683
- Methysergide**; migraine therapy; review, 365
- Metrizamide**; drug interactions; toxicity, pharmacology, review, 510
- Migraine**; therapy; review, 365
- Minoxidil**; hypotensive agents; review, 808
- Mithramycin**; injections; intravenous, stability, effects, cellulose ester membrane filters, 935
- Mixing**; additives, injections, polyvinyl chloride bags, methods, 1610
- Models**  
dosage schedules; pharmacokinetics, blood levels vs time profiles, 1631  
gentamicin; blood levels, hemodialysis patients, 1077  
nursing; primary, health care, delivery, 1089  
physicians; attitudes, prediction, use of pharmacists as drug information consultants, 483  
research; discussion, 541
- Monoamine oxidase inhibitors**; migraine therapy; review, 365
- N**
- Nafcilin**; stability; temperature, freezing, repackaged in disposable syringes, 1087
- Nalbuphine hydrochloride**; review, 942
- National Coordinating Committee on Large Volume Parenterals**  
economics; funding, views, FDA Commissioner, 738  
guidelines; additives, injections, i.v., quality assurance, centralized hospital services, 645; guidelines, injections, i.v., hospital pharmacists, 663  
Subcommittees on Dissemination of Results; injections, i.v., guidelines, 660
- Negligence**; pharmacists, institutional; legislation, determination, professional standards of due care, 1546
- Neomycin sulfate**; dosage forms; solids, stability, following unit dose packaging in hospital pharmacy, 165
- New Periodicals**, 125, 298, 427, 724, 1134, 1253, 1421, 1750
- News**, 135, 306, 430, 590, 738, 886, 1026, 1144, 1256, 1428, 1576, 1709
- Aging to be theme of 1981 AACN meeting, 1710  
Appointments and promotions, 139, 308, 439, 598, 744, 895, 1026, 1149, 1256, 1434, 1580, 1712  
Adams, Robert W., 744; Alford, C. Wendell, 746; Ashworth, Laurel E., 746; Baker, Carol, 1712; Baker, Daniel E., 1712; Baker, Thomas W., 1149; Baluch, Bill, 1149; Bartilucci, Andrew J., 310; Bateman, Mark, 1712; Baumgartner, R. Paul Jr., 1256; Boehm, Michael R., 1256; Benedict, L. Kirk, 1580; Bennett, Donald L., 896; Bergen, John V., 1149; Birmingham, Patrick H., 1026; Bond, Ray, 1149; Borruso, Richard D., 1152; Brown, Roger M., 439; Burke, W. Arthur, 139; Cain, Robert J., 1256; Chamberlain, Marvin, 1149; Coarse, James F., 896; Colalucia, Daniel M., 746; Dameron, C. Emory, 746; Del Prato, Pierre, 598; DeVine, Anita, 1712; Duncan, Edgar N., 139, 896; DuPont, Virginia L., 1712; Durgin, Sister Jane M., 1149; Edwards, Drew, 1149; Edwards, J. R. Eric, 439; Evans, R. Lee, 308; Fendler, Kermit J., 310; Fish, Kenneth H. Jr., 744; Fontana, Louis C., 896; Fredrick, David S., 1580; Goetz, Thomas E., 598; Goldberg, Renee J., 1712; Griffiths, David E., 1580; Griffin, Richard E., 1580; Harding, Roland F., 1026; Haun, W. Michael, 1256; Hay, Eugene F., 1580; Heinrich, William J., 1256; Humma, K. Gregory, 1256; Ives, Timothy J., 1712; Ivey, Marianne, 1149; Jacobs, J. Barry, 439; Jackson, Richard Allen, 744; Jeffrey, Paul L., 1580; Jones, Fredric E., 744; Jorgensen, Robert T., 1580; Kaplan, Mark, 744; Katz, Robert M., 598; Kaul, Alan F., 139; Kellerman, Donald J., 1712; Kendall, Ralph, 1712; Kimball, Bruce, 896; Knowles, Mark R., 746; Kuzmowicz, Marta K., 1434; Lakoff, Warren, 744; Lantos, Robert, 1712; Lauper, R. David, 1149; Leister, Kathy, 1149; Lemay, Arthur F., 1026; Lemberger, August P., 746; Lladia, Michael G., 1712; Lopez, A. Vincent, 744; Lucarotti, Richard L., 744; Maddox, Ronald W., 746; Marr, Frank, 139; Martinelli, Louis C., 896; Matthews, Hewitt W., 746; Mayo, Charles E., 1149; McMenamy, Sister Jane, 1580; McMillan, Dennis, 746; McPherson, Michael A., 744; McQuarrie, Gary M., 1256; Michaels, Alvin J., 896; Mitchell, Gary W., 896; Mitchell, John F., 896; Molecki, Ronald J., 896; Moore, Richard, 1149; 'lowry, James B., 1712; Mrtek, Robert G., 746; Muno, Francis J. Jr., 1712; Nault, Don, 1149; Newton, David W., 1028; Paiva, Kenneth B., 746; Pannell, Jeff, 139; Paravaccia, Vincent J., 139; Pesko, Larry, 439; Plotz, Pamela, 744; Posey, L. Michael, 1256; Pyke, Richard, 1028; Rivera-Ortiz, José O., 1580; Roques, Emile B., 746; Rosenberg, Howard A., 310; Russell, John V., 1580; Ryan, Patrick B., 308; Satkosky, Joseph, 896; Schultz, Warren L., 1256; Schwallie, Gary L., 1580; Scott, Dale, 1149; Sherman, Brian D., 139; Simmons, Steve, 746; Slight, Stephen M., 1256; Sloan, Stephen, 1149; Smith, Marie A., 1580; Smith, Richard L., 1434; Solomon, Beverly A., 1152; Stotter, Mary Linda, 1256; Street, John P., 1256; Surduran, Walter N., 1712; Szeffer, Mary C., 1712; Tam, Carlos W., 1580; Taniguchi, Ted, 1149; Teal, Thomas W., 1028; Teixeira, J. Philip, 1149; Tejani, Behram, 1434; Tesdall, Les, 1580; Thawley, William A., 310; Thompson, Glen, 746; Thompson, Thomas J., 1256; Tow, May Y., 1712; Tripplett, Willis, 1256; Trygstad, Vernon, 746; Tsipis, Gaylene B., 1580; Vinall, James R., 1580; Waller, David J., 1256; Wallner, Jon N., 1580; Wiczorek, La Vonne, 308; Wilson, Joseph Jr., 746; Wissinger, Robert, 1026, 1256; Wood, Charles A. Jr., 896; Yakatan, Gerald J., 1580; Zost, Edward D., 746
- Article addresses problems of handling injectable chemotherapeutic drugs, 1711  
ASHP Research and Education Foundation opens 1980 awards program, 594  
Asian pharmacists meet in Japan, 1709  
Boards call for authority over i.v. fluid therapy and radiopharmaceuticals, 1144  
Burn and surgery fellowship offered for pharmacists, 1144  
Call for papers: 1981 Pan American Congress, 1710  
Committee projects 70,000 physician surplus by 1990; calls for research on nonphysician providers, 1709  
Common data base and more cooperation recommended for better control of toxic substances, 137  
Conference reviews implications of hospital mergers and consolidations, 888  
Courts challenge nurses' right to separate collective bargaining unit, 139  
CPSC lists drugs exempted from child-proof packaging requirements, 1144  
Developing nations look hard for natural drugs, 1428  
Disposal problems for radioactive medical wastes become more severe, 435  
Facility design laboratory, 1149  
Family practice—clinical pharmacy opportunities in the community setting, 740  
FDA Commissioner discusses issues of concern to hospital pharmacists, 738  
FIP advances international role at Madrid meeting, 1709  
FIP meets in Brighton, 138  
Franck Memorial Library to be dedicated during International Seminar in Jerusalem, 895  
Hazel E. Landeen, ASHP charter member, dies, 1432  
High-protein diet speeds oxidative drug metabolism, 807  
Hospital pharmacy research grants awarded, 308  
Immunopharmacology, drug surveillance highlight AAAS pharmaceutical sciences meeting, 1434  
Inpatient program leads to better self-medication at home, 306  
International seminar held in Jerusalem, 1710  
JCAH quality assurance seminars, 742  
Joint commission calls for more comprehensive monitoring of drugs as used in practice, 590  
Lilly surveys hospital pharmacy operations, 306  
Louis Jeffrey receives honorary degree, 308  
Many changes in JCAH standards affect pharmacy department, 430  
Meetings and Continuing Education Programs, 139, 310, 439, 598, 746, 896, 1028, 1152, 1256, 1434, 1580, 1712  
Michigan pharmacy technician survey, 1256  
National health planning goals are drafted, 891  
News briefs, 140, 310, 440, 600, 748, 1152, 1264, 1436, 1584, 1714  
Accreditation Manual for Hospitals, 1582; AHA Hospital Research and Educational Trust, 1582; American Institute of the History of Pharmacy, 1584; Anderson, Lisa Gail, 1156; Anderson, Robert J., 140; Arizona Poison and Drug Information Center, 1156; Arthritis Information Clearinghouse, 1267; Aseptic Techniques for Pharmacy Technicians, 1156; Association for the Advancement of Medical Instrumentation, 1582; Beckerman, Joseph H., 1272; Blumlein, Lewis W., Jr., 1582; Brokaw Hospital, 1582; Brown, Mary Louise, 1714; Burechson, Keith, 1267; Calhoun, Doris A., 1582; Campbell, R. Keith, 748; Center for Decubitus Ulcer Research, 1272; Chalmers, Robert K., 140; Coe, Fred A. Jr., 1582; Coghill, Marjorie M., 1156; Covinsky, Joel O., 140; Department of Health and Human Services, 310; Donehew, L. Colonel Gerald, 1582; Eggleston, Max W., 600; Emergency Management of Heat Illness, 600; Establishing a Nutritional Support Service, 1714; Eubanks, Patricia D., 1582; FDA carcinogen reports, 1714; Foster, Thomas S., 140; Fox-Villet Drug Company, 598; Goldman, Louis, 1272, 1584; George Washington University Medical Center, 1264; Goyan, Jers E., 1582; Griffin, Richard E., 1267; Guidelines for the Identification of Particles in Parenterals, 1584; Guidelines for Volunteer Participation in Immunization Programs, 1267; Health Resources Administration, 1714; Hoffman, Dennis M., 1156; Hospital Management Systems Society, 598; Hospital Survey Profile, 1582; Illinois Pharmaceutical Association, 1584; Janousek, Jerome P., 600; Jeffrey, Louis P., 1267; Joint Commission on Accreditation of Hospitals, 1584; Kessler, Herman, 1264; King, Rosalyn C., 1156; Leland, George T., 1156; Lemberger, August P., 600; Likoff, William, 1582; Lyons, Carl D., 1436; Mahaffey, Fred T., 600; Magarian, Robert A., 748; McCarthy, Ramona D., 1156; Medic Alert, 1435; Mehl, Bernard, 140; Miller, Russell R., 1584; National Center for Education Statistics, 310; National Medical Audiovisual Center, 1582; National Science Foundation, 140; National Wholesale Druggists' Association, 1436; New England Council of Hospital Pharmacists, 748; Owyang, Eric, 1267; Perlman, David S., 598; PharmAlert, 748; Pharmacy Computerized Information System—Request for Proposal, 1582; Quality Assurance and the Pharmacist, 1714; Rational Geriatric Drug Therapy, 1267; Rawlings, John L., 1156; Richardson, Charles G., 1584; Richardson, Lillian C., 1584; Robayo, Juan E., 1714; Robinson, Ira C., 1156; Samuels, Thomas M., 1582; Schlossberg, Elias, 440; Schwartz, Arthur E., 310; SIOP Poison Prevention Program, 1714; The Sister M. Gonzales Pharmacy

Award, 1584; Sister Jeanette, O. P., 140; Smith, William E., Jr., 1436; Storch, H., 1272; Stout, Dennis, 1714; *Street Pharmacologist*, 1714; Sunflower Hospital Alliance for Resources Economy, Inc., 598; Uhl, Arthur H., 598; University of Kansas Medical Center, 1267; University of North Carolina at Chapel Hill School of Pharmacy, 1714; University of Pittsburgh, 1714; University of Rhode Island, 1584; University of Southern California School of Pharmacy, 310; University of Washington, 1156; The Upjohn Company Medical Bioavailability Unit, 1152; Vertical laminar flow containment hood program, 440; Washington Hospital Center, 1272; Weaver, Richard, 1156; Wells, Patrick R., 1156; Wilson, Molly Lucille, 1582; Wyatt, Benji, 1284; *Your Future in Pharmacy*, 598; Zoloth, Arthur M., 140

1979 Lilly hospital pharmacy survey, 1028

NIH consensus conference suggests treatment of febrile seizures usually not necessary, 1432

NRC advisory committee considers changing physician-licensing criteria for use of radioisotopes, 594

Nutritional support team shows decreased complications with TPN therapy, 1144

Official names change for 14 drugs, 1144

Older, low income patients reject generic drugs, 1576

OTA study assesses federal vaccine-related policies and options, 135

Plants again most common poison among children under five years, 1712

Postmarketing surveillance and status of pharmacy discussed by FDA Commissioner Goyan, 886

Practice trends of male and female pharmacists analyzed, 1432

Public Health Service launches "Project Sleep," 306

Relations between hospital pharmacists and state boards of pharmacy range from good to bad, 592

Research to analyze hospital's medication delivery system, 1026

Role of adjuvant chemotherapy in breast cancer addressed by NIH panel, 1576

"Sodium Chloride Injection" no longer means only 0.9%, 1144

State societies of hospital pharmacists move toward accepting technician members, 434

State voluntary effort committees surveyed, 1149

Study concludes that cost-benefit analysis of health-care technology is of limited use, 1576

Thrombolytics are the ideal therapy for acute deep-vein thrombosis and pulmonary embolism, NIH panel concludes, 1256

Updated information on ordering products from the Center for Disease Control, 1026

U.S. General Accounting Office recommends monitoring hospital supply price lists, 892

USP-adopted monograph titles to become official on July 1, 1980, 744

Variations in potency of levothyroxine tablets reported, 1711

What was that name again?, 305

**Nitroglycerin**  
additives; incompatibilities, containers, glass, polyvinyl chloride, polyolefin, 618  
stability; injections, i.v., effects, filters, containers and administration sets, 201

**Nomenclature**  
drugs; generic, tables, Great Britain and U.S., 624  
osmolality; discussion, 504  
osmolarity; discussion, 504  
research; methodology, reliability and validity of measures, 851

**Nurses**; antineoplastic agents; labeling, with hospital pharmacists, 1617

**Nursing**; primary; effects, pharmacy services, hospitals, 1091; 1093; health care, delivery, models, 1089

**Nursing homes**; drug interactions; computers, monitoring, patient profile, 385

**Nutrition**  
enteral; rational therapy, patients, 65  
ulcers; stress, therapy, review 1651

**Nutrition, parenteral**  
amino acids; solutions, pH, titration curves, 388  
FreAmino II; solutions, incompatibilities, sodium phosphate and calcium chloride or calcium gluconate, 673  
iron dextran; formulations, stability, 206  
Nystatin; suspensions; unit dose, institutions, need, survey, 780

**O**

**Orphenadrine citrate**; skeletal muscle relaxants; review, 1313

**Osmolality**; nomenclature; discussion, 504

**Osmolarity**; nomenclature; discussion, 504

**Oxytocin**  
ergonovine maleate; injections, i.v., stability, lack, effects, cellulose ester membrane filters, 935  
oxytocin; injections, i.v., stability, lack, effects, cellulose

ester membrane filters, 935

**Oxytocin**; injections; intravenous, stability, lack, effects, cellulose ester membrane filters, 935

## P

**Package inserts**; patients; laws, history, FDA, 1660; pharmacists, hospital, legal implications, 1656; regulations, FDA, pharmacists positive approach, 1487; views, FDA Commissioner, 738

**Packaging**  
antibiotics; syringes, freezing, temperature, effects on stability, 1089  
drugs; injections, solutions, suspensions, effects, repackaging, on stability, 680  
unit dose; aminophylline, tablets, cellophane, stability, 1046; dosage forms, solid, hospital pharmacy, effects, stability, shelf conditions, 165

**Paramethadione**; interactions; tests, laboratory, interference, 12-channel autoanalyzer, 1333

**Parasympatholytic agents**; rhinitis, vasomotor; therapy, discussion, 1496

**Parasympathomimetic agents**; colitis, ulcerative; therapy, review, 1635

**Parenteral nutrition**  
calcium gluconate; formulations, patient, 1474  
dextrose; toxicity, blood coagulation, due to inline filter, patients, 1616  
formulations; computers, calculation, 22; incompatibilities, trace elements, 1620

**Parenterals, see Injections**

**Patient information**  
comprehension; tests, reading levels, 215  
consultation; adverse reactions, pharmacists, physicians attitudes, 243; drug information, literature, evaluation, 1509; effects, compliance, hypertension clinic, 379; long-term care facilities, effects, drug consumption and costs, 92; pharmacists, drug information, consumers, service, 1176; pharmacists, role, pediatric ambulatory care clinics, 1339  
diazepam; labeling, tests, readability, evaluations, 1594  
forms; pharmacists, hospital, use in therapy assessment, 1616  
package inserts; laws, history, FDA, 1660; pharmacists, hospital, legal implications, 1656; regulations, FDA, pharmacists positive approach, 1487; views, FDA Commissioner, 738  
profile; drug interactions, monitoring, geriatrics, 385; long-term care facilities, effects, drug consumption and costs, 92; pharmacists, role, rational therapy, ambulatory clinic patients, comparison, physician assessments, 824  
warfarin sodium; comprehension, effects, reading levels and attitude, 240

**Patients**  
drug information; consultation, literature, evaluation, 1309  
maternity; discharge, poisoning control kits, 789

**Pediatrics**  
ambulatory care; clinics, clinical and distributive pharmacy services, 1339  
creatinine; excretion, comparison, methods, 1514  
creatinine clearance; methodology, comparison, 195  
parenteral nutrition; formulations, calculation, computers, 22  
sedatives; thiopental, comparison, chlorpromazine, combination, meperidine, promethazine, computerized tomography, 222  
sweetening agents; formulations, fluorides, combination, vitamins, 1048

**Pentazocine hydrochloride**; injections; stability, room temperature, following repackaging, 680

**Personnel**  
drug information centers; consumers, university, description, 1206; hours, services, consumers and health professionals, 1215

**Personnel, pharmacy**  
additives; injections, control, quality, microbiological contamination, aseptic operator technique, 668  
education; additives, injections, i.v., centralized hospital service, 645; intravenous therapy, guidelines, Subcommittee on Dissemination of Results of the National Coordinating Committee on Large Volume Parenterals, 660  
hospitals; services, shared, small rural, 1534  
intravenous therapy; guidelines, Subcommittee on Dissemination of Results of the National Coordinating Committee on Large Volume Parenterals, 660  
supportive; education, and training, formalization and standardization, discussion, 1300; effects, primary nursing, 1093; regulations, states and duties, discussion, 460; technicians, duties, hospitals, state board regulations, 592; technicians, hospitals, job satisfaction, 359; technicians, pharmaceutical services, decentralized, team, pharmacy service unit, 78; technicians, role, future, hospitals, discussion, 481; technicians, sterile products, standards, training and performance, 1311;

technicians, time studies, preparation, cephalothin sodium, i.v. piggyback injections, 1342; technicians, workload, audit, unit dose drug distribution systems, 85

workload; methodology, distributive and clinical services, 53

**Pharmaceutical education, see Education, pharmaceutical**

**Pharmaceutical services**

additives; centralized, hospitals, guidelines, quality assurance, 645  
ambulatory care, clinics, pediatrics, 1339  
centralized; long-term care facilities, effects, drug consumption and costs, 92  
hospitals; decentralized, team, pharmacy service unit, 78; effects, primary nursing, 1091, 1093; Joint Commission on Accreditation of Hospitals, standards, 430  
quality assurance, hospitals, programs, management corporation, 82  
shared; hospitals, small rural, 1534  
skilled nursing facilities; clinical pharmacists, contractual, effects, rational therapy, 820  
workload; methodology, distributive and clinical, 53

**Pharmacists**

consultation; adverse reactions, patients, physicians attitudes, 243; ambulatory care, clinics, pediatrics, 1339; drug information, consumers, service, 1176; patients, ambulatory, clinic, rational therapy, comparison, physician assessments, 824  
drug information; role, consultant, models, prediction of physician use, 483; systems, statewide, role, consumers and health professionals, 1211  
drug information centers; consumers, university, role, 1206; services, consumers, and health professionals, 1215

education; continuing, research methodology, 107  
health care; role, views, FDA Commissioner, 886  
rational therapy; patients, ambulatory, clinic, comparison, physician assessments, 824  
reimbursement; Health Systems Agencies, and State Health Planning and Development Agencies, 1072; pharmacokinetics, consultation service, hospital, 1466  
role; education, anticoagulants, patients, program, audit, 89; package inserts, patients, regulations, FDA, positive approach, 1487

**Pharmacists, community**

drug information; sources, survey, Michigan, 687  
state boards; members, effects, regulations, hospital pharmacy practice, 592

**Pharmacists, hospital**

ambulatory care; role, 801  
antineoplastic agents; labeling, with nurses, 1617  
consultation; effects, rational therapy, anti-infective agents and antibiotics, 829  
drug information; sources, survey, Michigan, 687  
forms; patient information, use in therapy assessment, 1616  
injections; guidelines, National Coordinating Committee on Large Volume Parenterals, 663  
Legislative Alert System; participation, discussion, 160

package inserts; patients, legal implications, 1656  
poisoning; control, kits, maternity discharge patients, 789

records; medical notation, policy, 16

rehabilitation, vocational; role, 1178

salaries; residencies, and benefits, 1980 survey, 1292

services; shared, small rural, 1534

team; pharmaceutical services, decentralized, pharmacy service unit, 78

workload; drug distribution systems, unit dose, audits, 85; methodology, distributive and clinical services, 53; workload; parenteral nutrition, formulations, calculation, computers, 22

**Pharmacists, institutional**; negligence; legislation, determination, professional standards of due care, 1546

**Pharmacogenetics**; chronopharmacology; therapy, effects, discussion, 101

**Pharmacokinetics**

amikacin; weight, effects, morbidly obese patients, 519

antibiotics; aminoglycosides, calculators, dosage schedules and blood levels, 225; dosage schedules, computers, meningitis or bacteremia patients, 523; dosage schedules, methodology, 1356

anti-infective agents; dosage schedules, computers, meningitis or bacteremia patients, 523

consultation; service, and costs, clinical pharmacists, hospitals, 1466

dosage schedules; computers, models, blood levels vs time profiles, 1631

gentamicin; blood levels, models, hemodialysis patients, 1087

geriatrics; dosage schedules, review, 559

lithium carbonate; capsules, humans, 1528

minoxidil; review, 808

phenytoin; dosage schedules, methodology, 128

theophylline; dosage schedules, i.v., toxicity, discussion, 49



# Pharmacokinetics in Drug Therapy, 128, 559, 1356

**Pharmacy**  
clinical, see **Clinical pharmacy**  
education, see **Education, pharmaceutical**  
health care; planning, role, Health Systems Agencies and State Health Planning and Development Agencies, 1072  
personnel, see **Personnel, pharmacy**  
state boards; regulations, pharmacists, community, members, effects, hospital pharmacy practice, 592  
**Pharmacy, community;** prescriptions; statistics, rational therapy, clinical effectiveness, 833  
**Pharmacy, institutional**  
mental retardation facilities; anticonvulsants, therapy, forms, blood levels and dosage, inpatients, 772  
nystatin; suspensions, unit dose, need, survey, 780  
pediatric; clinics, ambulatory care, 1339  
**Pharmacy, institutional, hospital**  
additives; injections, i.v., centralized services, guidelines, quality assurance, 645  
antineoplastic agents; injections, manufacturing, equipment, 1184  
Canada; discussion, 501  
cephalothin sodium; injections, i.v., piggyback, preparation, equipment, costs, technician time, 1342  
clinical pharmacy; services, costs, research design, problems, 1290; services, shared, 1306  
controlled substances; monitoring, system, based upon Controlled Substances Act, 1296  
costs; drugs, inventory control and purchasing, indexes, 837  
drug distribution systems; unit dose, audits, pharmacists and technicians, 85  
history; future, clinical services and technician use, 481  
negligence; legislation, determination, professional standards of due care, 1546  
package inserts; patients, legal implications, 1656  
packaging; unit dose, solids, stability, shelf conditions, 165  
pharmacokinetics; consultation, service, and costs, clinical pharmacists, 1466  
poisoning; control, kits, maternity discharge patients, 789  
quality assurance; programs, management corporation, 82  
radiopharmaceuticals; wastes, disposal, discussion, 435  
regulations; state boards, effects, community pharmacist members, 592  
services; decentralized, team, pharmacy service unit, 78; effects, primary nursing, 1091; 1093; shared, small rural, 1534  
technicians; education, and training, standards, sterile products, 1311; salaries, job satisfaction, 359  
ticrynafen; drug information, computers, formulary and recall, 1305  
workload; methodology, distributive and clinical services, 53  
**Pharmacy services;** shared; hospitals, clinical, 1306  
**Phenacetin;** interactions; tests, laboratory, phosphotungstic uric acid, discussion, 1458  
**Phenobarbital;** blood levels; analysis, role, clinical pharmacists, 61  
**Phenothiazines;** toxicity; eye, therapy, review, 74  
**Phenylpropanolamine;** rhinitis, vasomotor; therapy, discussion, 1496  
**Phenytoin**  
blood levels; analysis, role, clinical pharmacists, 61  
dosage; schedules; calculators, programmable, prediction, 529; methodology, pharmacokinetics, 128; pharmacokinetics, computers, models, blood levels vs time profiles, patients, 1631  
package inserts; patients, pharmacists, hospital, legal implications, 1656  
solubility; additives, large volume parenterals, 1647  
suspensions; oral, stability, room temperature, following repackaging, 680  
**Phenytoin sodium**  
dosage; single, oral, pharmacokinetics and side effects, patients, 232  
stability; additives, i.v., comparison, dextrose and sodium chloride, 95; additives, precipitation, large volume parenterals, 1647  
**Physicians**  
attitudes; pharmacists, consultation, adverse reactions, 243  
drug information; models, attitudes, prediction, use of pharmacists as consultants, 483  
drug information centers; consumers, university, role, 1206; services, consumers, and health professionals, 1215  
prescribing; anti-infective agents and antibiotics, hospitals, effects, clinical pharmaceutical services on rational therapy, 829; statistics, rational therapy, clinical effectiveness, 833  
rational therapy; patients, ambulatory, clinic, comparison, pharmacist assessments, 824  
**Pigmentation agents;** methoxsalen; package inserts,

patients, pharmacists, hospital, legal implications, 1656

**Plastics**  
containers; adsorption, diazepam, injections, i.v., 492; adsorption, insulin, effects, blood, 1323; diazepam, injections, effects, availability and stability, 496; incompatibilities, additives, nitroglycerin, 613; incompatibilities, Amin-Aid, disintegration, 464; nitroglycerin, injections, i.v., stability, effects, 201; lack, effects, bretylium tosylate incompatibilities, additives, 903  
syringes; stability, tobramycin sulfate, 1614  
**Poisoning**  
control; kits, maternity discharge patients, 789  
information; prevention, services, pharmacists, role, ambulatory care, pediatric clinic, 1339  
**Policies and procedures**  
intravenous therapy; guidelines, Subcommittee on Dissemination of Results of the National Coordinating Committee on Large Volume Parenterals, 660  
records; medical, hospitals, pharmacists' notations, 16  
**Polyolefins;** containers, incompatibilities, nitroglycerin, additives, 618; lack, effects, incompatibilities, verapamil hydrochloride and additives, 676  
**Polyvinyl chloride;** containers; cefazolin sodium, admixtures, stability, thawing, microwave radiation, 211; diazepam, injections, i.v., effects, stability, 492; incompatibilities, nitroglycerin, additives, 618; lack, effects, incompatibilities, verapamil hydrochloride and additives, 676; mixing, additives, methods, 1610; stability, cefamandole nafate injections, 98  
**Postmarketing surveillance;** drugs; views, FDA Commissioner, 886  
**Potassium chloride;** additives; injections, mixing, polyvinyl chloride bags, methods, 1610  
**Potassium iodide;** combination, iodine; solutions, formulations, 1048  
**Potassium phosphate;** incompatibilities; dobutamine hydrochloride, visual, 460  
**Povidone-iodine;** incompatibilities; acetone, combination, alcohols, ethyl, denatonium benzoate, isopropyl, acetone, loss, free iodine, 464  
**Precipitates;** fluorouracil; injections, lack, effects, microwave radiation, on stability, 678  
**Precipitation;** phenytoin; additives, large volume parenterals, 1647  
**Prescriptions**  
drug use review; long-term care facilities, effects, consumption and costs, 92  
prescribing; statistics, rational therapy, clinical effectiveness, 833  
**Procainamide;** stability; additives, injections, water and dextrose, combination, sodium chloride, 1050  
**Procainamide hydrochloride;** stability; additives, injections, dextrose, combination, sodium chloride, 1050  
**Professional fees;** clinical pharmacists; skilled nursing facilities, contractual, effects, rational therapy, 820  
**Promethazine;** combination, chlorpromazine, mepredine; comparison, thiopental, sedatives, pediatrics, computerized tomography, 222  
**Promethazine hydrochloride;** injections; stability, room temperature, following repackaging, 680  
**Propoxyphene;** package inserts; patients, pharmacists, hospital, legal implications, 1656  
**Propranolol**  
blood levels; analysis, role, clinical pharmacists, 61  
migraine therapy; review, 365  
**Pseudoephedrine;** rhinitis, vasomotor; therapy, discussion, 1496  
**Pseudoephedrine hydrochloride;** combination, triprolidine; dosage forms, solid, stability, following unit dose repackaging in hospital pharmacy, 165  
**Psoriasis;** oral; psoriasis, review, 814  
**Psoriasis;** therapy; review, 814  
**Psychotherapeutic agents**  
lithium; blood levels, relation, saliva levels, manic depressive patients, 514  
lithium carbonate; capsules, generic equivalency, availability, humans, 1528; interactions, antineoplastic agents, neutropenia, cancer patients, 1068; leukocytosis, patients, 1525  
**Purchasing;** drugs; hospital pharmacy, indexes, 837

## Q

**Quality assurance**  
additives; injections, i.v., guidelines, centralized hospital services, 645  
blood levels; drugs, analysis, role, clinical pharmacists, 61  
curriculum; education, pharmaceutical, undergraduate, discussion, 922  
education; anticoagulants, patients, programs, by pharmacists, 89  
hospital pharmacy; drug distribution systems; unit dose, audits, 85; programs, management corporation, 82  
pharmaceutical services; methodology, distributive and clinical, 53

**Questionnaires;** data collection; methodology, 1113  
**Questions and Answers,** 47, 185, 350, 478, 638, 798, 930, 1055, 1188, 1308, 1484, 1627  
Acquiring topic-specific references, 350  
Clinical privileges for pharmacists, 1484  
Code of ethics, 185  
Computer records for controlled substances, 185  
Computerized order entry by a physician's assistant, 1188  
Cost of membership services, 478  
Drug shortage monitoring program, 1188  
Expiration dating of drugs repackaged in unit dose form, 1308  
Inline i.v. filters, 798  
JCAH requirements for quality assurance programs, 1627  
Legal implications of salary surveys, 1627  
Liability implications of excluding dantrolene sodium injection from a hospital formulary, 930  
Locking and security of unit dose carts, 798  
Multidose vials, 185  
Nurse transcription of physicians' orders, 47  
Patients' own medication, 47  
Pharmacist transmission of physicians' orders to nurses, 478  
Pharmacist-conducted patient discharge counseling, 1055  
Preparing respiratory therapy doses, 798  
Public relations for hospital pharmacists, 638  
Reporting losses of controlled substances, 638  
Revision priorities for the American Hospital Formulary Service, 185  
Staffing requirements, 479  
Unit dose packages for outpatients, 1055  
"Voluntary" PPIs, 350  
**Quinidine;** blood levels; analysis, role, clinical pharmacists, 61

## R

**Radiation;** microwaves; cefazolin sodium, admixtures, stability, thawing, 211; fluorouracil, injections, precipitates, dissolution, lack, effects, stability, 678  
**Radioimmunoassay**  
digoxin; blood levels, increased, interactions, spironolactone, cirrhotic patients, 1518  
gentamicin; blood levels, results, comparison, enzyme multiplied immunoassay, 1049  
**Radioisotopes;** wastes; disposal, discussion, 435  
**Radiopharmaceuticals**  
indium In-111 oxine; leukocytes, labeling, method, 848  
wastes; disposal, discussion, 435  
**Rational therapy**  
antibiotics; computers, role, meningitis or bacteremia patients, 523; effects, clinical pharmaceutical services, hospitals, 829  
anticonvulsants; forms, mental retardation facilities, inpatients, 772  
anti-infective agents; computers, role, meningitis or bacteremia patients, 523; effects, clinical pharmaceutical services, hospitals, 829  
cimetidine; inpatients, 1462  
colitis, ulcerative; review, 1635  
digoxin; blood levels, analysis, hospitals, 1466  
erythromycin; review, 1199  
**Food and Drug Administration;** role, view, Commissioner, 886  
migraine headaches; review, 365  
minoxidil; review, 808  
nabuphine hydrochloride; review, 942  
nutrition; enteral, patients, 65  
patients; ambulatory, clinic, pharmacists, role, comparison, physician assessments, 824  
prescriptions; pharmacy, community, statistics, 833  
psoriasis; topical and systemic treatment, review, 814  
rhinitis, vasomotor; review, 1496  
skeletal muscle relaxants; review, 1313  
skilled nursing facilities; clinical pharmacists, contractual, effects, 829  
ulcers; stress, review, 1851  
vaginits; review, 1061  
**Reading;** comprehension; patient information, tests, levels, 215; patient information, warfarin sodium, 240  
**Records;** medical; hospitals, pharmacists' notations, policy, 16  
**Regulations**  
drugs, reform, views, FDA Commissioner, 738  
Food and Drug Administration; vitamins, multiple, injections, formulations, 789  
formularies; Medicaid, Louisiana, critique, 1350  
health care; planning, pharmacy, role, Health Systems Agencies and State Health Planning and Development Agencies, 1072  
package inserts; patients, FDA, pharmacists positive approach, 1487  
personnel, pharmacy; supportive, states, discussion, 450  
pharmacy; state boards, pharmacists, community,

## Index

members, effects, hospital pharmacy practice, 592  
**Rehabilitation, vocational;** pharmacists, hospital; role, 1178

**Replacement solutions**  
 calcium chloride; incompatibilities, dobutamine hydrochloride, visual, 460  
 calcium gluconate; incompatibilities, dobutamine hydrochloride, visual, 460  
 magnesium sulfate, incompatibilities, dobutamine hydrochloride, visual, 460  
 potassium phosphate; incompatibilities, dobutamine hydrochloride, visual, 460

## Research

clinical pharmacy; services, costs, design problems, 1290  
 data; methodology, interpretation, 1394; statistics, interpretation, 1673

design; methodology, discussion, 396  
 methodology; data, hypothesis testing, 1539; designs, and models, discussion, 541; hypotheses, characteristic, 264; hypotheses, and questions, 287; nomenclature, reliability and validity of measures, 861; pharmacists, continuing education, 107; sampling techniques, 998; types, discussion, 694

**Research Methods**, 107, 257, 398, 541, 694, 851, 998, 1113, 1235, 1394, 1539, 1673

## Resistance

antibiotics; computers, prediction, meningitis or bacteremia patients, 523  
 anti-infective agents; computers, prediction, meningitis or bacteremia patients, 523

**Rhinitis; vasomotor;** therapy, discussion, 1496

**Ringer's injection lactated;** additives; diazepam, injections, 496

## S

**Saccharin;** comparison, sucrose, sorbitol; taste, activated charcoal, formulations, 237

## Salaries

personnel, pharmacy; technicians, hospitals, job satisfaction, 359  
 residencies; hospitals, and benefits, 1980 survey, 1292

**Salicylates;** blood levels; analysis, role, clinical pharmacists, 61

**Saliva levels;** lithium; relation, blood levels, manic depressive patients, 514

**Sedatives;** migraine therapy; review, 365

## Sedatives and hypnotics

chlorpromazine, combination, meperidine, promethazine; comparison, thiopental, pediatrics, computerized tomography, 222

meperidine, combination, chlorpromazine, promethazine; comparison, thiopental, pediatrics, computerized tomography, 222

promethazine, combination, chlorpromazine, meperidine; comparison, thiopental, pediatrics, computerized tomography, 222

thiopental; comparison, chlorpromazine, combination, meperidine, promethazine, pediatrics, computerized tomography, 222

**Sex;** patients; effects, creatinine clearance following gentamicin therapy, 1489

**Skeletal muscle relaxants;** review, 1313

**Skilled nursing facilities;** clinical pharmacists; pharmaceutical services, contractual, effects, rational therapy, 830

**Sociology;** physicians; attitudes, drug information, use of pharmacists as consultants, 483

## Sodium bicarbonate

and dextrose or sodium chloride; incompatibilities, carmustine, room temperature, 677

nutrition, parenteral; amino acids, solutions, pH, titration curves, 336

## Sodium chloride

additives; diazepam, injections, i.v., 492; effects, i.v., phenytoin sodium, 30; injections, stability, effects, cellulose ester membrane filters, 935; nitroglycerin, incompatibilities, containers, polyvinyl chloride, polyolefin, glass, 618

admixtures; cefazolin sodium, stability, thawing, microwave radiation, 211

alone and with sodium bicarbonate; incompatibilities, carmustine, room temperature, 677

combination, dextrose; additives, effects, procainamide stability, 1050

diluents; cefamandole nafate, injections, effects, stability, 96

injections; intravenous, drop size, effects, administration sets, 1346

**Sodium hydroxide;** nutrition, parenteral; amino acids, solutions, pH, titration curves, 388

**Sodium iodide;** incompatibilities; lack, parenteral nutrition, formulations, 1620

**Sodium phosphate;** incompatibilities; calcium chloride, or calcium gluconate, FreAmine II solutions, 673

## Solubility

fluorouracil; injections, precipitates, dissolution, lack,

effects, microwave radiation, 678

phenytoin; aqueous, additives, large volume parenterals, 1647

phenytoin sodium; additives, i.v., comparison, dextrose and sodium chloride, 95

## Solutions

fluorouracil; stability, amber glass containers, effects, temperature, pH, 164

haloperidol; oral, stability, room temperature, following repackaging, 680

iodine, combination, potassium iodide; formulations, 1048

isoetharine; inhalation, stability, room temperature, following repackaging, 680

mannitol; stability, temperature, storage kettle, 16

potassium iodide, combination, iodine; formulations, 1048

sterility; technicians, hospital pharmacy, training and procedures, 1311

**Solvents;** injections; phenytoin sodium, additives, effects, phenytoin solubility, large volume parenterals, 1647

**Sorbitol;** comparison, saccharin, sucrose; taste, activated charcoal formulations, 237

## Spasmolytics

aminophylline; dosage forms, solid, stability, following unit dose repackaging in hospital pharmacy, 165; interactions, tests, laboratory, phosphotungstic acid, lack, patients, 1522; tablets, availability, patients, 1618; tablets, stability, packaging, unit dose, cellophane, 1046

theophylline; dosage schedules, pharmacokinetics, computers, models, blood levels vs time profiles, patients, 1631; dosage schedules, i.v., toxicity, discussion, 49

**Spectrometry, ultraviolet;** tolbutamide; tablets, equivalency, generic, 1329

**Spirolactones;** interactions; digoxin, blood levels, increased, radioimmunoassay, cirrhotic patients, 1518

## Stability

additives; injections, effects, cellulose ester membrane filters, 935

aminophylline; tablets, packaging, unit dose, cellophane, 1046

brevityllyl tosylate; incompatibilities, additives, injections, glass and plastic containers, 803

calcium chloride and sodium phosphate; FreAmine II solutions, 673

calcium gluconate and sodium phosphate; FreAmine II solutions, 673

carmustine; additives, sodium chloride, dextrose, sodium bicarbonate, room temperature, 677

cefamandole; temperature, freezing, repackaged in disposable syringes, 1087

cefamandole nafate; effects, light and reconstitution, 334; injections, chemical, microbiological and visual, 98

cefazolin; alone and with lidocaine, temperature, freezing, repackaged in disposable syringes, 1087

cefazolin sodium; admixtures, thawing, microwave radiation, 211

cephalothin; temperature, freezing, repackaged in disposable syringes, 1087

cimetidine hydrochloride; additives, injections, visual and chemical, 390

diazepam; injections, effects, containers and administration sets, 496; injections, i.v., effects, containers and administration sets, 492

dobutamine, hydrochloride; incompatibilities, additives, visual, 460

dosage forms; solids, following unit dose repackaging in hospital pharmacy, shelf conditions, 165

edotat disodium; incompatibilities, additives, possible, discussion, 174

fluorouracil; injections, precipitates, dissolution, lack, effects, microwave radiation, 678; solutions, amber glass containers, effects, temperature, pH, 164

haloperidol; solutions, oral, room temperature, following repackaging, 680

insulin; adsorption, containers, i.v., glass and plastics, effects, blood, 1323

isoetharine; solutions, inhalation, room temperature, following repackaging, 680

iron dextran; formulations, parenteral nutrient solutions, 206

lidocaine and cefazolin; temperature, freezing, repackaged in disposable syringes, 1087

mannitol; solutions, temperature, storage kettle, 16

naicillin; temperature, freezing, repackaged in disposable syringes, 1087

nitroglycerin; additives; incompatibilities, containers, glass, polyvinyl chloride, polyolefin, 618; injections, i.v., effects, filters, containers and administration sets, 201

parenteral nutrition; formulations, incompatibilities, trace elements, 1620

pentazocine hydrochloride; injections, room temperature, following repackaging, 680

phenytoin; suspensions, oral, room temperature, following repackaging, 680

phenytoin sodium; additives, i.v., comparison, dextrose and sodium chloride, 95; additives, precipitation, large volume parenterals, 1647

plastics; containers, incompatibilities, Amin-Aid, disintegration, 464

procainamide; additives, injections, water and dextrose, combination, sodium chloride, 1050

promethazine hydrochloride; injections, room temperature, following repackaging, 680

sodium phosphate and calcium chloride or calcium gluconate; FreAmine II solutions, 673

tobramycin; incompatibilities, ticarcillin, in vitro blood samples, 920

tobramycin sulfate; syringes, plastics, 1614

verapamil hydrochloride; additives, injections, glass and plastic containers, 678

**Stabilizers;** edotat disodium; incompatibilities, additives, injections, possible, discussion, 174

## Standards

education, pharmaceutical; technicians, sterile products, training and performance, 1311

hospitals; Joint Commission on Accreditation of Hospitals, effects, pharmaceutical services, 430

pharmacists; institutional; negligence, determination of due care, 1546

**State Health Planning and Development Agencies;** pharmacists; role, 1072

## Statistics

drug information; physicians, attitudes, models, prediction, use of pharmacists as consultants, 483

prescriptions; pharmacy, community, rational therapy, clinical effectiveness, 833

research; data, interpretation; 1673

salaries; residencies, hospitals, and benefits, 1980 survey, 1292

## Sterility

additives; injections, control, quality, cumulative sum control charts, 655

injections; and solutions, technicians, hospital pharmacy, standards, training and performance, 1311

## Steroids, corticosteroids

colitis, ulcerative; therapy, review, 1635

rhinitis, vasomotor; therapy, discussion, 1496

ulcers; stress, therapy, review, 1651

## Storage

aminophylline; dosage forms, solid, stability, following unit dose repackaging in hospital pharmacy, 165; tablets, stability, packaging, unit dose, cellophane, 1046

antibiotics; packaging, syringes, freezing, temperature, effects on stability, 1087

brevityllyl tosylate; incompatibilities, additives, injections, glass and plastic containers, 803

fluorouracil; solutions, stability, shelf life, amber glass containers, effects, temperature, pH, 164

FreAmine II; solutions, effects, incompatibilities, sodium phosphate and calcium chloride or calcium gluconate, 673

iron dextran; formulations, stability, parenteral nutrient solutions, 206

phenytoin sodium; stability, additives, precipitation, large volume parenterals, 1647

**Sucrose;** comparison, saccharin, sorbitol; taste, activated charcoal formulations, 237

**Sulfasalazine;** colitis, ulcerative; therapy, review, 1635

**Sulfonamides;** interactions; tests, laboratory, interference, 12-channel autoanalyzer, 1333

## Surgical supplies

administration sets; diazepam, effects, concentration and flow rates, 1176; diazepam, injections, effects, availability and stability, 496; diazepam, injections, i.v., effects, stability, 492; injections, i.v., drop size, 1346; administration sets; nitroglycerin, injections, i.v., stability, effects, 201

hospitals; shared, small rural, 1534

## Suspensions

nystatin; unit dose, institutions, need, survey, 780

phenytoin; oral, stability, room temperature, following repackaging, 680

**Sweetening agents;** formulations; pediatrics, fluorides, combination, vitamins, 1048

## Sympathomimetic agents

phenylpropanolamine; rhinitis, vasomotor, therapy, discussion, 1496

pseudoephedrine hydrochloride, combination, triprolidine; dosage forms, solids, stability, following unit dose repackaging in hospital pharmacy, 165; rhinitis, vasomotor, therapy, discussion, 1496

## Syringes

antibiotic; packaging, temperature, freezing, effects on stability, 1087

drugs; stability, upon repackaging, 680

plastics; stability, tobramycin sulfate, 1614

## T

## Tablets

aminophylline; availability, patients, 1618; stability, packaging, unit dose, cellophane, 1046

tolbutamide; equivalency, generic, dissolution charac-

- teristics, 1329
- Taste:** charcoal activated; formulations, comparison, saccharin, sucrose, sorbitol, 237
- Temperature**
- bretylium tosylate; effects, incompatibilities, injections, additives, glass and plastic containers, 803
- calcium chloride and sodium phosphate; effects, stability, FreAmine II solutions, 673
- calcium gluconate and sodium phosphate; effects, stability, FreAmine II solutions, 673
- carmustine; stability, additives, sodium chloride, dextrose, sodium bicarbonate, 677
- cefamandole; freezing, effects, stability, repackaged in disposable syringes, 1087
- cefamandole nafate; stability, injections, glass and polyvinyl chloride containers, 96
- cefazolin; alone and with lidocaine, freezing, effects, stability, repackaged in disposable syringes, 1087
- cefazolin sodium; admixtures, stability, thawing, microwave radiation, 211
- cephalothin; freezing, effects, stability, repackaged in disposable syringes, 1087
- cimetidine hydrochloride; additives, injections, effects, stability, 390
- dosage forms; solids, effects, stability, following unit dose repackaging in hospital pharmacy, shelf conditions, 165
- fluorouracil; solutions, stability, amber glass containers, 164
- haloperidol; room, solutions, oral, stability, following repackaging, 680
- isotharine; room, solutions, inhalation, stability, following repackaging, 680
- iron dextran; formulations, stability, parenteral nutrient solutions, 206
- lidocaine and cefazolin; freezing, effects, stability, repackaged in disposable syringes, 1087
- mannitol; stability, solutions, storage kettle, 16
- nafcillin; freezing, effects, stability, repackaged in disposable syringes, 1087
- nitroglycerin; additives, lack, effects, stability, 618; injections, i.v., stability, effects, containers, glass and plastics, 201
- pentazocine hydrochloride; room, injections, stability, following repackaging, 680
- phenytoin; room, suspensions, oral, following repackaging, 680
- procainamide; additives, injections, lack, effects, stability, 1050
- promethazine hydrochloride; room, injections, stability, following repackaging, 680
- sodium phosphate and calcium chloride or calcium gluconate; effects, stability, FreAmine II solutions, 673
- tobramycin; incompatibilities, ticarcillin, in vitro blood sample, 920
- tobramycin sulfate; stability, plastic syringes, 1614
- Tee-Tape:** interactions; methylolpa, lack, patients, 683
- Tests**
- dissolution rates; tolbutamide, tablets, equivalency, generic, 1329
- readability; diazepam, patient information, labeling, evaluations, 1504
- Tests, laboratory**
- blood levels; tobramycin, radioimmunoassay, and microbiologic techniques, effects, carbenicillin interaction, patient, 702
- creatinine clearance; pediatric, comparison, methods, 105
- interactions; aminophylline, phosphotungstate uric acid, lack, patients, 1522; drugs, effects, phosphotungstate uric acid, discussion, 1458; drugs, interference, determination, 12-channel autoanalyzer, 1333; methylolpa, lack, effects, ClinTest, Tee-Tape and ClinTest, patients, 683
- Theophylline**
- blood levels; analysis, role, clinical pharmacists, 61; equivalency, following aminophylline tablets, patients, 1618; lack, effects, phosphotungstate uric acid test, patients, 1522
- dosage schedules; intravenous, toxicity, discussion, 49; pharmacokinetics, computers, models, blood levels vs time profiles, patients, 1631

- Therapeutics Bibliography for Clinical Pharmacists**, 406, 553, 711, 860
- Thiazides;** package inserts; patients, pharmacists, hospital, legal implications, 1656
- Thiocyanates;** blood levels; analysis, role, clinical pharmacists, 61
- Thiopental;** comparison, chlorpromazine, combination meperidine, promethazine; sedatives, pediatrics, computerized tomography, 222
- Ticarcillin;** incompatibilities; tobramycin, in vitro blood sample, 920
- Ticrynafen**
- drug information; computers, hospital pharmacy, formulary and recall, 1305
- interactions; aspirin, lack, effects, uric acid level, patient, 334
- Time studies;** technicians; hospital pharmacy, preparation, cephalothin sodium, i.v. piggyback injections, 1342
- Titrmetry;** amino acids; solutions, nutrition, parenteral, 388
- Tobramycin**
- incompatibilities; ticarcillin, in vitro blood sample, 920
- interactions; carbenicillin, effects, blood level, analysis, patient, 702
- Tobramycin sulfate;** stability; syringes, plastics, 1614
- Tolbutamide;** tablets; equivalency, generic, dissolution characteristics, 1329
- Topical preparations;** lidocaine; glossitis, therapy, doxepin-induced, patient, 1551
- Toxicity**
- cefazolin sodium; seizures, high CSF levels, renal failure patients, 271
- cimetidine; psychoses, patient, 1667; side effects, rational therapy, inpatients, 1482
- dextrose; parenteral nutrition, blood coagulation, due to inline filters, patients, 1616
- edetate disodium and elements, trace; paresthesia, parenteral nutrition patient, 1474
- elements, trace and edetate disodium; paresthesia, parenteral nutrition, patients, 1616
- filters; inline, blood coagulation, dextrose parenteral nutrition, patients, 1616
- lithium carbonate; leukocytosis, patients, 1625; neutropenia, mechanism of action, cancer patients, 1066
- metrizamide; side effects, review, 510
- minoxidil; review, 808
- nalbuphine hydrochloride; side effects, review, 942
- phenothiazines; eye, therapy, review, 74
- phenytoin sodium; side effects, single oral dose, patients, 232
- theophylline; dosage schedules, intravenous, discussion, 49
- vasoconstricting agents; contraindications, rebound congestion, vasomotor rhinitis, therapy, 1496
- Toxicity, environmental**
- antineoplastic agents; equipment, hospital pharmacy manufacturing, 1184
- radioisotopes; wastes, disposal, discussion, 435
- radiopharmaceuticals; wastes, disposal, discussion, 435
- Tranquilizers**
- diazepam; administration sets, effects, concentration and flow rates, 1176; injections, availability and stability, effects, containers and administration sets, 496; injections, i.v., stability, effects, containers and administration sets, 492
- haloperidol; solutions, oral, stability, room temperature, following repackaging, 680
- Travert;** additives, cimetidine hydrochloride, stability, visual and chemical, 390
- Tripolidine;** combination, pseudoephedrine hydrochloride; dosage forms, solid, stability, following unit dose repackaging in hospital pharmacy, 165

## U

- Ulcers**
- cimetidine; blood levels, relation, lack, gastric acidity, patients, 375

## Author Index

- Amann, Anton H. see also Lee, Ying-Chi, 803
- Ambrose, Thomas J. Training and monitoring of primary-care pharmacists (letter), 340
- Amerson, Ann B. Book review, 281
- Amerson, Ann B. see also Knodel, Leroy C., 1509
- Anderson, Ernest R. Jr. see Gouveia, William A., 1311
- Andresen, Brian D. see Ives, Timothy J., 683
- Angaran, David M. Editorial, 933
- Angaran, David M. Use of ClinTest urine test for indirect estimation of blood glucose levels in the critically ill, 956

- stress; drugs, therapy, review, 1651
- Unit dose drug distribution systems;** see **Drug distribution systems;** unit dose
- United States Pharmacopoeia;** injections; contamination, vials, multiple dose, lack, guidelines, 1610
- Uricosuric agents;** ticrynafen; interactions, aspirin, lack, effects, uric acid level, patient, 334

## V

- Vaginitis;** therapy; review, 1061
- Vasoconstricting agents**
- contraindications; rhinitis, vasomotor, therapy, rebound congestion, discussion, 1496
- epinephrine hydrochloride; asthma, acute, dosage, patients, 1326
- Vasodilating agents;** nitroglycerin; additives, incompatibilities, containers, glass, polyvinyl chloride, polyolefin, 618; stability, injections, i.v., effects, filters, containers and administration sets, 201
- Verapamil hydrochloride;** incompatibilities; lack, additives, glass and plastic containers, 675
- Vials;** injections; multiple dose, contamination, lack, guidelines, 1610
- Vinblastine sulfate;** injections; intravenous, stability, lack, effects, cellulose ester membrane filters, 935
- Vincristine sulfate;** injections; intravenous, stability, effects, cellulose ester membrane filters, 935
- Vitamin A;** ulcers; stress, therapy, review, 1651
- Vitamins**
- combination, fluorides; formulations, pediatrics, sweetening agents, 1048
- multiple; injections, formulations, FDA, 789
- Volume;** injections; phenytoin, effects, solubility, 1647

## W

- Warfarin**
- education; patients, programs, by pharmacists, audit, 89
- interactions; doxycycline, increased coagulation, patient, 1620
- package inserts; patients, pharmacists, hospital, legal implications, 1656
- Warfarin sodium**
- patient information; comprehension, effects, reading levels, and attitude, 240
- Water**
- additives; effects, procainamide stability, 1050
- dilutes; cefamandole nafate, injections, effects, stability, 98
- Weight**
- patients; amikacin, pharmacokinetics, morbidly obese patients, 519
- tolbutamide; tablets, equivalency, generic, 1329
- Workload**
- hospital pharmacy; methodology, distributive and clinical services, 53
- pharmacists; and technicians, drug distribution systems, unit dose, audits, 85; drug information, systems, statewide, role, consumers and health professionals, 1211; hospital; parenteral nutrition, formulations, calculations, computers, 22

## Z

- Zinc chloride;** incompatibilities; parenteral nutrition, formulations, 1620
- Zinc sulfate;** incompatibilities; parenteral nutrition, formulations, 1620

## A

- Alexander, Bruce see McGee, Jackie L., 1052
- Allen, Loyd V. Jr. Book review, 1688
- Allen, Loyd V. Jr. see also Frech, Gary, 1481
- Almquist, David D. Questions and answers, 185
- Amann, Anton H. Plastic i.v. container for nitroglycerin (letter), 618
- Amann, Anton H. see also Baaske, David M., 201
- Amann, Anton H. see also Gentzkow, Gary D., 623

- Anzalone, Richard see Witte, Kenneth, 99
- Archambault, James R. see Seitz, Dory J., 1614
- Argente, David J. Drug recall procedures: "There 'oughta' be a law" (letter), 1305
- Armstrong, William A. Jr. Analysis of drug-drug interactions in a geriatric population, 385
- Arcione, Frank J. see Poirier, Therese L., 687
- Athanikar, Narayan see Henry, R. Scott, 673
- Athanikar, Narayan K. see also Sturgeon, Roy J., 388
- Atkins, David see McKenney, James M., 824
- Avis, Kenneth E. see Morris, Beth G., 189, 668



# Index

- Ayres, James W. Lot-to-lot variation in dissolution of tolbutamide tablets, 1329  
Ayres, James W. see also Estabrook, David R. II, 1046

## B

- Baaske, David M. Nitroglycerin compatibility with intravenous fluid filters, containers, and administration sets, 201  
Baaske, David M. Stability of procainamide hydrochloride in dextrose solutions (letter), 1050  
Baaske, David M. see also Amann, Anton H., 618  
Baaske, David M. see also Lee, Ying-Chi, 803  
Bachynsky, John A. Hospital pharmacy in Canada, 501  
Baker, William J. see Beightol, Robert W., 847  
Baldicus, Joseph G. see Rosenberg, Howard A., 390  
Ball, William D. see Park, Glen D., 1290  
Balu, Venkataraman see Kimmelblatt, Bruce Jay, 408  
Barker, Kenneth N. Data collection techniques: Observation, 1235  
Barr, Judith T. see Schumacher, Gerald E., 187  
Barriere, Steven L. Treatment of systemic herpes encephalitis and herpes conjunctivitis—correction of an error (letter), 1625  
Bauer, Larry A. Amikacin pharmacokinetics in morbidly obese patients, 519  
Bauman, Jerry L. see Elenbaas, Robert M., 61  
Baumgartner, Thomas G. Book reviews, 280, 295  
Bauwens, Steven Kinetic model for intravenous heparin infusion (letter), 36  
Bechtel, Thomas P. Seizures associated with high cerebrospinal fluid concentrations of cefazolin, 271  
Beightol, Robert W. Labeling autologous leukocytes with indium-111 oxine, 847  
Bell, Alexander F. see Scott, Kenneth R., 16  
Bell, J. Edward Book review, 281  
Bell, Richard M. see Bauer, Larry A., 519  
Bennett, Sharon Wraith Computer-assisted customized antimicrobial dosages, 523  
Bergemann, Donald E. Checklist for evaluating management of controlled substances (letter), 1296  
Berger, Bruce A. see Covington, Tim R., 1300  
Birnbau, Marvin L. see Angaran, David M., 950  
Bivins, Brack see Rapp, Robert F., 634  
Blackwell, Barry see Rehder, Terry L., 379  
Blake, Martin I. see Weinstein, Marvin M., 1620  
Blanford, Marvin F. Book review, 1416  
Bloom, Phillip see Goetz, Darryl R., 1077  
Blouin, Robert A. see Bauer, Larry A., 519  
Bombeck, C. T. see Cohen, Ira A., 375  
Bond, William S. Ocular and cutaneous effects of chronic phenothiazine therapy, 74  
Bornstein, Michael Stability of frozen solutions of cefamandole nafate, 98  
Bossett, R. J. Request for information on cost benefits of pharmacy preparation of injection (letter), 466  
Bosse, John A. Book review, 1558  
Bowles, Grover C. see Morris, Beth G., 668  
Boyce, Eric Therapeutics of antirheumatic agents (letter), 341  
Boylan, James C. see Bornstein, Michael, 98  
Brandstetter, Robert D. Optimal dosing of epinephrine in acute asthma, 1326  
Brewer, Pamela K. see Broekemeier, Ronald L., 85  
Brier, Kenneth see Dasta, Joseph F., 1176  
Brink-Johnson, Truls see Seitz, Dory J., 1614  
Broekemeier, Ronald L. Audit mechanism for hospital drug distribution, 85  
Bryan, Candace K. see Rudd, G. David, 1514  
Bryant, Bobby G. Treatment of psoriasis, 814  
Burekatt, Gilbert J. Rectal thiopental versus an intramuscular cocktail for sedating children before computerized tomography, 222  
Burke, Wayne S. Nephrology, 587  
Bustrack, James A. see DiPiro, Joseph T., 1518  
Bustrack, James A. see also Foster, Thomas S., 1528  
Butler, Lynn D. Effect of inline filtration on the potency of low-dose drugs, 935

## C

- Campagna, Keith D. see Witte, Kenneth W., 520  
Campagna, Mary Ann see Witte, Kenneth, 59  
Canada, Andrew T. see Marion, Athan, 341  
Canfield, B. G. see Glasco, G. P., 22  
Carasiti, Mary Ellen see McKenney, James M., 834  
Cardi, Vincent Reconstituting cefamandole and protecting from light (letter), 334  
Carmichael, Ronald R. Solubility and stability of phenytoin sodium when mixed with intravenous solutions, 95  
Cartier, James E. see Baaske, David M., 201, 1050  
Cartier, James E. see also Lee, Ying-Chi, 803  
Cerra, Frank B. see Slaughter, Richard L., 1083  
Chase, Patricia Poison control kits for new mothers

- (letter), 789  
Chase, Patricia Widening the distribution of poison control kits (letter), 1614  
Chatterji, Dulal C. Incompatibility of povidone-iodine with Laveol (letter), 464  
Chenella, Frank C. Kinetic model for intravenous heparin infusion (letter), 37  
Chernoff, Ronal Enteral feedings, 65  
Cheung, Alan Book review, 574  
Chrymko, Margaret Pediatrics, 713  
Churchill, William W. see Souney, Paul F., 1048  
Clark, Beverly G. see Strandberg, Lee R., 92  
Clarke, Diana F. Hematology, 553  
Clasen, Thomas E. Ineffective top selling drugs (letter), 1186  
Clayton, Bruce D. Book review, 1698  
Clifford, Joyce C. Primary nursing: A contemporary model for delivery of care, 1069  
Cloyd, James C. Availability of diazepam from plastic containers, 492  
Clute, Shirley S. see Montagne, Michael, 1211  
Cluxton, Robert J. Book review, 579  
Clyne, Kurt E. Chelating agent in non-USF calcium gluconate injection (letter), 1474  
Cearse, James F. Hospital pharmacy indexes: A tool for assessing purchasing and inventory control performance, 837  
Coburn, Middleton J. Job satisfaction of hospital pharmacy technicians in North Carolina, 359  
Cohen, Ira A. Book review, 1249  
Cohen, Ira A. Relationship between cimetidine plasma levels and gastric acidity in acutely ill patients, 375  
Colaluca, Daniel M. see Kerchner, Julie, 1323  
Collins, Edward Book review, 1693  
Colvin, Michael Stability of carmustine in the presence of sodium bicarbonate, 677  
Comstock, Thomas J. see Russo, John Jr., 843  
Conner, Christopher S. Book review, 1412  
Conner, Christopher S. Drug information services for consumers and health professionals, 1215  
Cooney, David O. Palatability of sucrose, sorbitol-, and saccharin-sweetened activated charcoal formulations, 237  
Cote, John R. see DiPiro, Joseph T., 1518  
Covington, Tim R. Supportive personnel in pharmacy (letter), 1300  
Crass, Richard E. see Foster, Thomas S., 1528  
Cronk, Jack D. Television commercials that boost pharmacy's image (letter), 1048  
Cronk, Jack D. see also Matzke, Gary R., 1049  
Cutis, Maria R. Compatibility of verapamil hydrochloride injection in commonly used large-volume parenterals, 675

## D

- Dahlin, Patricia A. Visual compatibility of dobutamine with seven parenteral drug products (letter), 460  
Dana, William J. Book review, 1412  
Daniels, Charles E. Effect of control programs on cefazolin prescribing—correction of an error (letter), 24  
Dasta, Joseph F. Loss of diazepam to drug delivery systems (letter), 1176  
Davis, Larry see McKenney, James M., 824  
Dawson, Gary W. see Strandberg, Lee R., 92  
Deardorff, Dwight L. Mixing additives in plastic LVPs (letter), 1610  
Deardorff, Dwight L. Osmotic strength, osmolality, and osmolarity, 504  
Delaney, Colleen see Kwok, Florence, 1618  
de Leon, Richard F. see Levin, Robert H., 53  
DeLuca, Patrick P. see Butler, Lynn D., 935  
DeLuca, Patrick see also Rapp, Robert F., 634  
Depew, Charles C. Potential hazards with Rap-Add syringes (letter), 622  
DiPiro, Cecily R. see DiPiro, Joseph T., 1518  
DiPiro, Joseph T. Spiroolactone interference with digoxin radioimmunoassay in cirrhotic patients, 1518  
Donta, Sam T. see Prince, Randall A., 1499  
Dougherty, John T. see Rosenberg, Howard A., 390  
Dozi, Amelia Questions and answers, 798, 1065, 1484  
Dreiman, Randall Kent Comparison of six methods of preparing piggyback doses of cephalothin sodium, 1342  
Driever, Carl W. see Armstrong, William A. Jr., 385  
Dufala, Mary E. Labeling antineoplastic drugs (letter), 1817  
Dukes, George E. see Bauwens, Steven, 26

## E

- Eaton, Margaret L. Patient comprehension of written drug information, 240  
Eckel, Frederick M. see Coburn, Middleton J., 359  
Eicheleberger, Bernadette M. News, 434, 740  
Ekins, Brent R. Book review, 284

- Elenbaas, Julia Keiko Centrally acting oral skeletal muscle relaxants, 1313  
Elenbaas, Robert M. Influence of clinical pharmacist consultations on the use of drug blood level tests, 61  
Enright, Sharon M. Questions and answers, 478  
Estabrook, David R. II Stability of uncoupled aminophylline tablets in unit dose packages (letter), 1046  
Evens, Ronald P. Phenytoin toxicity and blood levels after a large oral dose, 232  
Evens, Ronald P. Therapeutics of antirheumatic agents (letter), 346

## F

- Fallavollita, Alfred Jr. see Curtal, Arthur L., 1305  
Farrell, Brett T. see Bornstein, Michael, 98  
Fink, Joseph L. III Legal standard of due care for pharmacists in institutional practice, 1546  
Fischer, John M. Modification of the systematic approach to answering drug information requests (letter), 470  
Fisher, Diane J. Influence of attitudes, normative beliefs, and situational variables on physicians' use of pharmacists as drug information consultants, 483  
Fisher, Diane J. see also Pathak, Dev S., 998  
Fites, Alan L. Reconstituting cefamandole and protecting from light (letter), 334  
Fitzgerald, Charles Jr. Chelating agent in non-USF calcium gluconate injection (letter), 1478  
Floyd, Ronald A. see Chenella, Frank C., 37  
Ford, Pamela S. see Conner, Christopher S., 1215  
Foster, Thomas S. Disulfiram-like reaction associated with a parenteral cephalosporin, 858  
Foster, Thomas S. Evaluation of two lithium carbonate formulations, 1528  
Fraser, Donald G. Selection of an oral erythromycin product, 1199  
Fraser, Donald G. see also Evens, Ronald P., 232  
Frear, Raulo S. Ticrynafene-induced uricemia with concurrent aspirin therapy (letter), 334  
Frech, Gary Clinical implications of preserving TPN solutions with sodium acetate (letter), 1481  
Friedman, David S. Endocrinology, 410  
Friedman, Lee Correct nomenclature for coal tar solution (letter), 1482

## G

- Gagnon, Jean Paul see Coburn, Middleton J., 359  
Gallina, Joseph N. see Jeffrey, Louis P., 78  
Garcia, Loni T. Pharmacy supportive personnel (letter), 1183  
Garnett, William R. see Moss, Richard L., 243  
Garrison, Thomas J. Book review, 574  
Geiger, Gail S. see Greenlaw, Cal Wayne, 1466  
Gentskow, Gary D. Potential hazards with Rap-Add syringes (letter), 623  
Glasco, G. P. Computerized total parenteral nutrition formulas for newborn infants (letter), 22  
Gibson, Charles D. Comparison of word-processing equipment (letter), 636  
Gill, Mark A. Altered gentamicin distribution in septic patients (letter), 634  
Gill, Mark A. see also Chenella, Frank C., 37  
Gleaser, Malcolm A. see Gurtel, Arthur L., 1305  
Goetz, Darryl R. Prediction of serum gentamicin concentrations in patients undergoing hemodialysis, 1077  
Goldstein, Ellis J. C. see Ma, Mary Y., 24  
Gots, Vincent P. Folic acid hypersensitivity or tartrazine allergy? (letter), 1470  
Gots, Vincent P. see also Brandstetter, Robert D., 1326  
Gourley, Dick R. Book review, 1562  
Gouveia, William A. Editorial, 1311  
Grabowski, Bonnie S. Shared pharmaceutical services in small hospitals, 1534  
Grant, Dov see Yoselson-Superstine, Shimona, 1333, 1458, 1522  
Grant, Kathryn L. Book review, 284  
Green, Elaine Finkelstein see Chrymko, Margaret, 713  
Greenberg, Robert B. Institutional pharmacists' guide to complying with PPI regulations, 1666  
Greenberg, Robert B. Questions and answers, 185, 350, 538, 798, 930, 1627  
Greenlaw, Cal Wayne Use of digoxin serum assays in a nonteaching hospital (letter), 1466  
Greifenhagen, Robert Training and monitoring of primary-care pharmacists (letter), 340  
Griffen, Ward O. Jr. see Bauer, Larry A., 519  
Gualtieri, C. T. see Rosman, Allen W., 860  
Gumpert, Norman F. see Lee, Boush, 1176  
Gupta, Alka see Gupta, V. Das, 165  
Gupta, V. Das Stability of oral solid drugs after repackaging in single-unit containers (letter), 165  
Gurtel, Arthur L. Computer assistance for the P&T

committee (letter), 1305  
 Gurwich, Ernest Book review, 1418  
 Gurwich, Ernest L. see also Witte, Kenneth, 89

## H

Halberg, Franz Chronopharmacology: A therapeutic frontier, 101  
 Hamilton, Robert A. Altered gentamicin distribution in ascitic patients (letter), 626  
 Hanus, Philip M. Metrizamide: A review with emphasis on drug interactions, 510  
 Hartner, Judith see Colvin, Michael, 677  
 Haug, Marcus T. III see Greenlaw, Cal Wayne, 1466  
 Hauser, Louis see Hayman, Jim, 22  
 Hayman, Jim Classification changes in the *American Hospital Formulary Service* (letter), 22  
 Hays, Robert L. see Armstrong, William A. Jr., 385  
 Hazlet, Thomas K. Book review, 1693  
 Hazlet, Thomas K. Clinical implications of preserving TPN solutions with sodium acetate (letter), 1480  
 Heiser, William D. see Raasch, Ralph H., 412  
 Heller, William M. Time limits on the use of opened multiple-dose vials (letter), 1610  
 Hendeles, Leslie, Editorial, 49  
 Hendeles, Leslie Medical management of noninfectious rhinitis, 1496  
 Hendeles, Leslie Poor absorption of an un-theophylline xanthine bronchodilator (letter), 169  
 Hendeles, Leslie Theophylline content of intravenous aminophylline (letter), 926  
 Henricks, Jacalyn Newman Using pharmacokinetics in drug therapy. VIII. Pharmacokinetic evaluation of antibiotic dosage regimens, 1356  
 Henry, R. Scott Compatibility of calcium chloride and calcium gluconate with sodium phosphate in a mixed TPN solution, 873  
 Henry, R. Scott see also Sturgeon, Roy J., 388  
 Hepler, Charles D. Problems and hypotheses, 257  
 Hepler, Charles D. Use of simulation to develop multiple-dose regimens for drugs exhibiting nonlinear elimination kinetics, 1631  
 Hepler, Charles D. see also Prince, Randall A., 1489  
 Hermann, Freya Book review, 1416  
 Hetey, Stephen K. Effect of ascorbic acid on urine pH in patients with injured spinal cords, 235  
 Hibbard, F. James Book review, 1562  
 Hillbrand, Thelma C. Theophylline content of intravenous aminophylline (letter), 924  
 Hills, John R. see Scheife, Richard T., 365  
 Hirsch, Jerry I. Use of blue dyes in lymphography (letter), 1182  
 Hoag, Stephen, see Goetz, Darryl R., 1077  
 Holloway, Richard L. see Eaton, Margaret L., 240  
 Hopkins, Leigh E. see Lee, Mary, 1086  
 Hood, Jerry C. see Chatterji, Dulal C., 464  
 Horn, John Book review, 574  
 Horowitz, Kenneth N. Design and implementation of a quality-assurance program for pharmaceutical services, 82  
 Hoyt, Harvey J. see Baaske, David M., 201  
 Hulka, Scott see Dunafala, Mary E., 1617  
 Hull, J. Heyward see Rudd, G. David, 1514  
 Hunt, Stephanie see Matzke, Gary R., 1049  
 Hutchinson, Richard A. see Witte, Kenneth W., 829  
 Hynnan, Clifford E. Responding to the challenges of a new decade, 969

## I

Iafrate, R. Peter Nonindicated use of cimetidine (letter), 1462  
 Inoue, Fumio Epileptic seizure charts (letter), 772  
 Ives, Timothy J. Doxepin-induced acute glossitis, 1551  
 Ives, Timothy J. Effect of methylidopa on urine glucose test methods, 683

## J

Jabbour, J. T. see Burckart, Gilbert J., 222  
 Jackowitz, Arthur I. Ulcerative colitis and its treatment, 1635  
 Jackson, Richard A. Interpretation of research data: Selected statistical procedures, 1673  
 Jacobs, J. Harry Book review, 1686  
 Jang, Raymond General purpose of research designs, 398  
 Jeffrey, Louis P. Pharmacy service units: The evolution of a concept, 78  
 Jeffrey, Louis P. Survey of salaries and benefits received by residents (letter), 1292  
 Jeffrey, Louis P. see also Carmichael, Ronald R., 95  
 Jeffrey, Louis P. see also Oliver, Ernest J., 460  
 Johnson, Cary E. see Traub, Scott L., 195

Johnson, Curtis A. see Letendre, Donald E., 775  
 Johnson, Ernest W. see Hetey, Stephen K., 235  
 Johnson, Mary K. see Broekemeier, Ronald L., 85  
 Jones, Barry C. see Tomecko, G. William Jr., 211  
 Juhl, Randy P. see Kerchner, Julie, 1323  
 Jump, Walter G. Filtering TPN solutions containing trace elements or insulin (letter), 1615  
 Jurgens, Raymond W. Jr. see Henry, R. Scott, 673  
 Jurgens, Raymond W. Jr. see also Sturgeon, Roy J., 388

## K

Kabat, Hugh F. see Halberg, Franz, 101  
 Kapoor, John see Murty, Ram, 789  
 Katcher, Brian S. Book review, 1251  
 Katz, Michael D. Infection in a functioning ventriculo-peritoneal shunt treated with intraventricular gentamicin, 268  
 Katz, Michael D. Intraventricular gentamicin administration (letter), 928  
 Kaul, Alan F. see Souney, Paul F., 1048  
 Kawada, Charles Y. Treatment of systemic herpes encephalitis and herpes conjunctivitis—correction of an error (letter), 1625  
 Kawada, Charles Y. Treatment of vaginitis, 1061  
 Kayser, Steven R. Book review, 579  
 Kealey, Gerald P. see Prince, Randall A., 1489  
 Kennelly, William Readability of article on readability (letter), 1474  
 Kepler, Judith A. Questions and answers, 185  
 Kerchner, Julie Effect of whole blood on insulin adsorption onto intravenous infusion systems, 1323  
 Kern, Jack W. see Chenella, Frank C., 37  
 Kiernan, William E. see Kresel, James J., 1178  
 Kimelblatt, Bruce Jay Cardiology, 408  
 Kirschenbaum, Harold L. see Sessin, George P., 1474  
 Klapp, Deborah Quality assurance training for pharmacy students (letter), 922  
 Klein, Patrick see Halberg, Franz, 101  
 Kleinberg, Michael L. Book review, 1562  
 Kleinberg, Michael L. Effect of microwave radiation on redissolving precipitated matter in fluorouracil injection, 678  
 Kleinberg, Michael L. Stability of antibiotics frozen and stored in disposable hypodermic syringes, 1087  
 Kleinberg, Michael L. Stability of five liquid drug products after unit dose repackaging, 680  
 Kleinberg, Michael L. see also Hetey, Stephen K., 235  
 Kleinberg, Michael L. see also Tomecko, G. William Jr., 211  
 Kline, Berry J. see Polk, Ron E., 920  
 Klink, Paul R. see Bornstein, Michael, 98  
 Kluz, Ronald B. see Newton, David W., 1647  
 Knodel, Leroy C. Evaluation of patient medication counseling sources, 1509  
 Koup, Jeffrey R. see Slaughter, Richard L., 1083  
 Kowalsky, Steven F. see Prince, Randall A., 1489  
 Kradjan, Wayne A. see Kwok, Florence, 1618  
 Kresel, James J. Pharmacy-based vocational rehabilitation (letter), 1178  
 Kresel, James J. see also Seitz, Dory J., 1614  
 Kubica, Anthony J. see Coarse, James F., 837  
 Kwok, Florence Comparative bioavailability of two uncoated aminophylline tablets (letter), 1618

## L

Lacina, Norman C. Book review, 1693  
 Ladik, Carole F. Precautionary measures in the preparation of antineoplastics (letter), 1184  
 Lai, Chi-Ming, see Lee, Ying-Chi, 803  
 Lakshminarayan, S. see Kwok, Florence, 1618  
 Lambert, Ivan see Traub, Scott, 464  
 Lambert, Randall L. see Manasse, Henri R. Jr., 694  
 Lamin, Marlene see Horowitz, Kenneth N., 82  
 Lapierre, Ginette Lithium carbonate and leukocytosis, 1525  
 Latolais, Clifton J. see Kleinberg, Michael L., 678, 680, 1087  
 Latolais, Clifton J. see also Tomecko, G. William Jr., 211  
 Lauper, R. David see Gotz, Vincent P., 1470  
 LeBel, Marc Risk-benefit equation for erythromycin estolate (letter), 176  
 Lech, John G. Book review, 1560  
 Lee, Beulah Book review, 1688  
 Lee, Beulah Pilot project of a statewide consumer drug information service (letter), 1176  
 Lee, Charles S. see Wang, Lo-Hwa, 956  
 Lee, Harland E. Effects of primary nursing on pharmaceutical services, 1093  
 Lee, Mary Attenuation of chemotherapy-induced neutropenia with lithium carbonate, 1066  
 Lee, Ying-Chi Brevityl tosylate intravenous admixture compatibility. I: Stability in common large-volume

parenteral solutions, 803  
 Leeds, Norman H. see Witte, Kenneth W., 820  
 LeFrock, Jack L. see Prince, Randall A., 1489  
 Lesko, Lawrence J. see Marion, Athan, 341  
 Letcher, Kenneth I. Comparison of word-processing equipment (letter), 636  
 Letcher, Kenneth I. see also Levin, Robert H., 53  
 Letendre, Donald E. Cephalothin-induced urinary precipitation (letter), 775  
 Levin, Robert H. Patient-care unit system for measuring clinical and distributive pharmacy workload, 53  
 Levinson, R. Saul see Frech, Gary, 1481  
 Ling, Michael H. see Prince, Randall A., 1489  
 Lipman, Arthur G. see Russo, John Jr., 843  
 Lopes, Larry M. see Russell, Wayne L., 1467  
 Lord, Nicholas G. see Cutie, Maria R., 675  
 Love, David W. see Miller, Delwyn D., 808  
 Ludden, Thomas M. see Evans, Ronald P., 232  
 Lombard, James B. Book review, 724

## M

Ma, Mary Y. Effect of control programs on cefazolin prescribing—correction of an error (letter), 24  
 MacCarra, Mary E. see Parker, William A., 496  
 Madden, Richard W. Inline filters (letter), 634  
 Mahoney, Charles D. see Carmichael, Ronald R., 95  
 Mahoney, Charles D. see also Jeffrey, Louis P., 1292  
 Mahoney, Charles D. see also Oliver, Ernest J., 460  
 Malick, A. Waseem see Baaske, David M., 1050  
 Manasse, Henri R. Jr. Types of research: A synopsis of the major categories and data collection methods, 694  
 Mar, Dexter D. Book review, 122  
 Mar, Dexter D. see also Brandstatter, Robert D., 1326  
 Marbury, Thomas C. see Wang, Lo-Hwa, 956  
 Marion, Athan Problems with laboratory method of measuring thiazides in urine (letter), 341  
 Mathison, Donald see Strandberg, Lee R., 92  
 Matyas, Jeffrey G. Patient monitoring form (letter), 1616  
 Matzke, Gary R. Accuracy of gentamicin assays (letter), 1049  
 Maurer, Mary Ann see Ladik, Carole F., 1184  
 Mayron, David see Rosenberg, Howard A., 390  
 McCarty, Gary M. see Levin, Robert H., 53  
 McCoy, Linda K. see Rehder, Terry L., 379  
 McGee, Jackie L. Lithium citrate syrup and trifluoperazine hydrochloride concentrate incompatibility: Effect on serum lithium levels (letter), 1062  
 McGhee, William G. see Chenella, Frank C., 37  
 McGhan, William F. see Stergachis, Andreas S., 1072  
 McKennell, Thomas see Montagne, Michael, 1211  
 McKenney, James M. Drug therapy assessments by pharmacists, 824  
 Meade, Richard H. III Risk-benefit equation for erythromycin estolate (letter), 180  
 Meinhold, Jane M. see Pathak, Dev S., 996  
 Meisel, Steven Altered gentamicin distribution in ascitic patients (letter), 626  
 Merkus, F. W. H. M. see Zuidema, J., 169  
 Merrick, Idana M. Comparison of drop sizes of intravenous administration sets, 1346  
 Merrick, Thomas E. see Merrick, Idana M., 1346  
 Meyer, Richard D. see Ma, Mary Y., 24  
 Michelson, Paul A. Altered gentamicin distribution in ascitic patients (letter), 625  
 Mickey, Ray see Ma, Mary Y., 24  
 Mikel, Robert L. Research design: General designs, 541  
 Milkovich, Gary The pharmacist's role in infection control (letter), 790  
 Miller, Delwyn Evaluation of minoxidil, 808  
 Miller, Kenneth W. see Cloyd, James C., 492  
 Miller, Russell R. Evaluation of nalbuphine hydrochloride, 942  
 Milovanovic, D. Stability of fluorouracil in amber glass bottles (letter), 164  
 Mintzer, Deborah L. see Westfall, Lawrence K., 1620  
 Montagne, Michael A statewide decentralized public drug information system, 1211  
 Mooers, Martha see Baaske, David M., 201  
 Mooers, Martha A. see also Lee, Ying-Chi, 803  
 Moore, Dennis F. Book review, 291  
 Moore, Robert C. Regulating investigational drugs (letter), 625  
 Moore, Timothy D. see Bechtel, Thomas P., 271  
 Morris, Beth G. Quality-control plan for intravenous admixture programs. I: Visual inspection of solutions and environmental testing, 189  
 Morris, Beth G. Quality-control plan for intravenous admixture programs. II: Validation of operator technique, 668  
 Morris, C. Richard see Rudd, G. David, 1514  
 Morris, Louis A. Application of the readability concept to patient-oriented drug information, 1504  
 Morse, M. Lee see Rucker, T. Donald, 1350  
 Moss, Richard L. Physician attitudes toward pharmacists counseling patients on adverse drug reactions, 243

Munson, James M. see Butler, Lynn D., 935  
 Munson, James M. see also Foster, Thomas S., 1528  
 Murakami, Kathryn see Conner, Christopher S., 1215  
 Murphy, Kelly J. see Conner, Christopher S., 1215  
 Murphy, John E. Carbamazepine-induced leukocytosis, 590  
 Murphy, John E. Filing of personal reference collections (letter), 618  
 Murty, Ram Reformulating parenteral multivitamin preparations (letter), 789  
 Myers, Ann see Morris, Louis A., 1504

## N

Nairn, J. G. see Milovanovic, D., 164  
 Nation, Roger see Cohen, Ira A., 375  
 National Coordinating Committee on Large Volume Parenterals Recommendations to pharmacists for solving problems with large-volume parenterals—1979, 663  
 National Coordinating Committee on Large Volume Parenterals Recommended guidelines for quality assurance in hospital centralized intravenous admixture services, 645  
 National Coordinating Committee on Large Volume Parenterals Recommended standards of practice, policies, and procedures for intravenous therapy 660  
 Nelson, Arthur A. Jr. Developing research hypotheses, 264  
 Nelson, Arthur A. Jr. Research design: Measurement, reliability, and validity, 851  
 Nelson, Arthur A. Jr. Research methods for pharmaceutical practice, 107  
 Nelson, Arthur A. Jr. see also Witte, Kenneth W., 829  
 Nelson, E. Don see Sigell, Leonard T., 1206  
 Newgreen, David B. Differences in English-language generic drug nomenclature (letter), 624  
 Newton, David W. Prediction of phenytoin solubility in intravenous admixtures: Physicochemical theory, 1647  
 Ng, Philip K. Determining aminoglycoside dosage and blood levels using a programmable calculator, 225  
 Ng, Philip K. Individualizing phenytoin dosage regimens using a programmable calculator, 529  
 Nordin, James D. see Scott, David M., 1339  
 Northern, Robert E. Request for information regarding pharmacy operation of a medical staff library (letter), 1183  
 Nyhus, L. M. see Cohen, Ira A., 375

## O

Oddis, Joseph A. Report of Executive Vice President, 976  
 O'Dell, John D. Defining the role of pharmaceutical industry representatives (letter), 1187  
 Okasa, Richard M. see Lee, Beulah, 1176  
 Oliver, Ernest J. State legislation pertaining to supportive personnel in pharmacy (letter), 460

## P

Page, Brent C. see Russo, John Jr., 843  
 Pakes, Gary E. see Rosman, Allen W., 514  
 Pancorbo, Salvador see Goetz, Darryl R., 1077  
 Paredes, Stephen M. see Dahlin, Patricia A., 460  
 Park, Glen D. Problems with evaluations of clinical pharmaceutical services (letter), 1290  
 Parker, Eugene A. Adding insulin to LifeCare flexible containers (letter), 1617  
 Parker, Roger E. see Sigell, Leonard T., 1206  
 Parker, Watson D. see Hetey, Stephen K., 235  
 Parker, William A. Book review, 1251  
 Parker, William A. Compatibility of diazepam with intravenous fluid containers and administration sets, 496  
 Parrott, Keith A. Drug waste in long-term care facilities: Impact of drug distribution system, 1531  
 Pathak, Dev S. Research design: Sampling techniques, 998  
 Pathak, Dev S. see also Fisher, Diane J., 483  
 Pathak, Dev S. see also Witte, Kenneth W., 820  
 Patterson, Larry E. see Petersen, Stephen D., 1466  
 Payne, Vaughn W. see Elenbaas, Robert M., 61  
 Perry, Paul J. see McGee, Jackie L., 1052  
 Pesko, Lawrence J. see Tomcko, G. William Jr., 211  
 Petersen, Stephen D. Reimbursement for pharmacokinetic consultation in a community hospital (letter), 1466  
 Petersen, Charles D. Book review, 1667  
 Pevonka, M. Peter see Ives, Timothy J., 683  
 Plascik, Mary Faust see Sigell, Leonard T., 1206  
 Plerino, Donna A. see Leucher, Kenneth I., 636  
 Plotz, Pamela H. see Theilke, Thomas S., 1091  
 Polier, Therese I. Printed drug information sources

used by pharmacists in southeastern Michigan, 687  
 Polk, Ron E. Mail order tobramycin serum levels: low values caused by ticarcillin (letter), 920  
 Pente, Charles D. Book review, 283  
 Ponto, James A. Questionable bioactivity of intrinsic factor for second-state Schilling test (letter), 1294  
 Poremba, Art see Jump, Walter G., 1615  
 Porter, R. Stephen Respiratory disease, 862  
 Prince, Randall A. Factors associated with creatinine clearance changes following gentamicin therapy, 1489  
 Prince, Randall A. see also Hepler, Charles D., 1631  
 Prior, Richard B. see Tomcko, G. William Jr., 211  
 Prior, Richard B. see also Kleinberg, Michael L., 1087

## Q

Quap, Curt W. Providing clinical services on a shared basis (letter), 1306

## R

Raasch, Ralph H. Gastroenterology, 412  
 Raehl, Cynthia L. see Foster, Thomas S., 858  
 Rainville, Edward C. see Prince, Randall A., 1489  
 Ramey, D. Randolph see Burckart, Gilbert J., 222  
 Rapp, Robert P. Inline filters (letter), 634  
 Rapp, Robert P. see also Katz, Michael D., 268, 928  
 Rawlings, John see Strandberg, Lee R., 92  
 Ray, Max D. Editorial, 1196  
 Ray, Max D. Questions and answers, 1627  
 Record, Kenneth E. see Bauer, Larry A., 519  
 Rehder, Terry L. Improving medication compliance by counseling and special prescription container, 379  
 Rhomberg, Mary A. News, 135, 137, 306, 307, 430, 435, 594, 1428  
 Riddiough, Michael A. Take your congressman to the Midyear (letter), 466  
 Roberts, Michael J. Interest in commercially available unit dose nystatin oral suspension (letter), 780  
 Robinson, Ann see Rehder, Terry L., 379  
 Robinson, Lawrence A. see Spadaro, Daniel C., 215  
 Rockey, Paul H. see Gurtel, Arthur L., 1305  
 Roffman, David S. Insulin resistance: Definition and treatment, 1105  
 Romankiewicz, John A. Nitroglycerin tablets not to be refrigerated (letter), 794  
 Rosenberg, Howard A. Cimetidine hydrochloride compatibility. I: Chemical aspects and room temperature stability in intravenous infusion fluids, 390  
 Rosman, Allen W. Correlation between saliva and serum lithium levels in manic-depressive patients, 514  
 Rosman, Allen W. Psychiatry, 860  
 Rosman, Allen W. Therapeutics bibliography for clinical pharmacists, 406  
 Rucker, T. Donald Book review, 1688  
 Rucker, T. Donald The Medicaid drug program in Louisiana: A critique of the Hefner-Fracon study, 1350  
 Rucker, T. Donald The top-selling drug products: How good are they?, 833  
 Rudd, G. David Estimating creatinine clearance in children: Comparison of three methods, 1514  
 Rumack, Barry H. see Conner, Christopher S., 1215  
 Russell, Wayne L. Cimetidine-induced mental status changes: Case report, 1667  
 Russell, Wayne L. see also Iafate, R. Peter, 1462  
 Russo, John Jr. Lidocaine anesthesia: Comparison of iontophoresis, injection, and swabbing, 843  
 Russo, Mary E. Penicillin-aminoglycoside inactivation: Another possible mechanism of interaction, 702

## S

Sanchez, Ronald J. Questions and answers, 638  
 Sanford, Roy L. Cumulative sum control charts for admixture quality control, 655  
 Sawyer, Dennis see Conner, Christopher S., 1215  
 Shrivast, Clyde see Hayman, Jim, 22  
 Scheffe, Richard T. Migraine headache: Signs and symptoms, biochemistry, and current therapy, 385  
 Schmidt, Clyde N. see Dardorff, Dwight L., 1610  
 Schneiweis, Fred Counterfeit amphetamines (letter), 1187  
 Schneiweis, Fred Feedback from users of a drug information center (letter), 1614  
 Schneiweis, Fred Potential for interactions between health foods and drugs (letter), 787  
 Schneiweis, Fred Sweetener content of fluoride-containing pediatric vitamin preparations (letter), 1048  
 Schonfeld, Steven see Dasta, Joseph F., 1176  
 Schumacher, Gerald E. Editorial, 187  
 Schumacher, Gerald E. Using pharmacokinetics in drug therapy. VI: Comparing methods for dealing with nonlinear drugs like phenytoin, 128  
 Schumacher, Gerald E. Using pharmacokinetics in drug

therapy. VII: Pharmacokinetic factors influencing drug therapy in the aged, 559  
 Schumacher, Gerald E. see also Henricks, Jacalyn Newman, 1356  
 Schweigert, Byron F. Book review, 284  
 Scoratow, Renee see Welch, Dennis, 174  
 Scott, A. Carlisle see Bennett, Sharon Wraith, 523  
 Scott, David M. Pharmacist's role in projects for children and youth, 1339  
 Scott, Kenneth R. Warming kettle for storing mannitol injection (letter), 16  
 Sczupak, Christine A. Neurology, 711  
 Sczupak, Christine A. see also Clarke, Diana F., 553  
 Sczupak, Christine A. see also Roman, Allen W., 514  
 Seitz, Dory J. Stability of tobramycin sulfate in plastic syringes (letter), 1614  
 Senin, George P. Folic acid hypersensitivity or tartrazine allergy? (letter), 1474  
 Shapiro, Howard S. Nephrology, 557  
 Sheahan, Jim Book review, 1698  
 Sigel, Frederick P. see Weinstein, Marvin M., 1620  
 Siegle, Robert L. see Burckart, Gilbert J., 222  
 Siepler, John K. see Cohen, Ira A., 375  
 Sigell, Leonard T. Consumer focus of a university drug and poison information center, 1206  
 Silis, Richard H. see Clarke, Diana F., 553  
 Skolaut, Milton W. Moving toward the 21st century, 355  
 Skolaut, Milton W. Report of Treasurer, 978  
 Skultety, F. Miles see Young, W. Wayne, 16  
 Slaughter, Richard L. Effect of hemodialysis on total body clearance of chloramphenicol, 1083  
 Slaughter, Richard L. see also Bechtel, Thomas P., 271  
 Smith, Dale F. see Angaran, David M., 950  
 Smith, L. Tracy see Spadaro, Daniel C., 215  
 Smith, Randall B. see Foster, Thomas S., 1528  
 Sones, Sheldon S. see Argento, David J., 1305  
 Sorkness, Ronald Infectious disease, 555  
 Souney, Paul F. Use and preparation of Schiller solution (letter), 1048  
 Spadaro, Daniel C. Assessing readability of patient information materials, 215  
 Springer, Phillip K. see Murphy, John E., 550  
 Spunt, Avery L. see Witte, Kenneth W., 820  
 Stauffer, Gene L. see Kleinberg, Michael L., 678, 680, 1087  
 Stein, Robert L. Use of inline filters and infusion pumps with TPN solutions (letter), 1616  
 Stein, Z. L. G. Effect of sodium thiosulfate on cisplatin (letter), 170  
 Stein, Z. L. G. Malignant melanoma and Vogt-Koyanagi-Harada syndrome (letter), 1306  
 Stein, Z. L. G. Reviewing current literature—imperative in providing clinical services (letter), 468  
 Steiner, Kenneth C. see Moss, Richard L., 243  
 Stennett, Douglas J. see Estabrook, David R. II, 1046  
 Stephen, Robert L. see Russo, John Jr., 843  
 Stephen, Stephen P. Book review, 1418  
 Stephenson, Robert E. Nitroglycerin tablets not to be refrigerated (letter), 794  
 Stergachis, Andreas S. Pharmacy and health planning: A national survey of health planners, 1072  
 Stewart, Kenneth R. see Gupta, V. Dae, 185  
 Stewart, Ronald B. Book review, 1698  
 Stewart, Ronald B. see also Ives, Timothy J., 1551  
 Stewart, Ronald B. see also Lapierre, Ginette, 1525  
 Stewart, Ronald B. see also Murphy, John E., 550  
 Stiles, M. Lou see Frech, Gary, 1481  
 Stohr, Gary P. see Ladik, Carole F., 1184  
 Stolar, Michael H. Interpretation of research data: Hypothesis testing, 1539  
 Stolar, Michael H. Questions and answers, 185, 479, 798, 1188, 1627  
 Stoll, Roger G. see Baaske, David M., 201  
 Stolley, Stephen N. Book review, 296  
 Strandberg, Lee R. Effect of comprehensive pharmaceutical services on drug use in long-term care facilities, 92  
 Sturgeon, Roy J. Titratable acidities of crystalline amino acid admixtures, 388  
 Sturgeon, Roy see also Henry, R. Scott, 673  
 Summerfield, Marc see Colvin, Michael, 677  
 Summerfield, Marc R. see also Roberts, Michael J., 780  
 Superstine, Edward see Yonelson-Superstine, Shimona, 1333, 1458, 1522  
 Sutherland, Earl W. III see Evans, Ronald P., 232  
 Swartz, Allan J. Book review, 292  
 Swartz, Allan J. Editorial, 353

## T

Talley, C. Richard Book reviews, 280, 587  
 Talley, C. Richard Editorials, 641, 1195  
 Talley, C. Richard News, 592, 888  
 Tanner, David J. see Dupew, Charles C., 622  
 Tanner, David J. see also Grabowski, Bonnie S., 1534  
 Tatro, David S. Book review, 280



- Ternes, Richard L. see Clyne, Kurt E., 1474  
 Thielke, Thomas S. Primary nursing and pharmacy systems: Are they compatible?, 1091  
 Thilman, Diane G. see Morris, Louis A., 1504  
 Thomas, Arend J. see Scott, Kenneth R., 16  
 Thompson, Arthur M. see Kressel, James J., 1178  
 Tomecko, G. William Jr. Stability of cefazolin sodium admixtures in plastic bags after thawing by microwave radiation, 211  
 Toussignant, Dwight R. Questions and answers, 47, 350  
 Traub, Scott L. Comparison of methods of estimating creatinine clearance in children, 195  
 Traub, Scott Possible incompatibility of an amino acid supplement with plastic cups (letter), 464  
 Tsailas, George see Wan Kwong, Kee, 206

## U

- Ulan, Martin S. see Quap, Curt W., 1306  
 Underwood, Fred L. The effect of energy conservation regulations on drug stability: A theoretical consideration (letter), 170

## V

- Van Leuven, Marcel see Henry, R. Scott, 673  
 Varano, Carmine Mistaken ingestion of camphorated oil for castor oil (letter), 176  
 Vetrano, Anthony J. Implications of the Lannett and Pharmacy decisions, 537  
 Vetrano, Anthony J. Questions and answers, 47, 478, 1055, 1188, 1308  
 Vezau, Claude see Cloyd, James C., 492  
 Vrabel, Rayburn B. see Hazlet, Thomas K., 1480

## W

- Wagenknecht, Dietmar M. see Amann, Anton H., 618

- Wagenknecht, Dietmar M. see also Baaske, David M., 201  
 Wagenknecht, Dietmar M. see also Lee, Ying-Chi, 803  
 Walsh, John W. see Katz, Michael D., 268, 928  
 Wan, Kwong Kee Dilute iron dextran formulation for addition to parenteral nutrient solutions, 206  
 Wang, Lo-Hwa Hemodialysis of mefenamic acid in uremic patients, 956  
 Warden, L. K. see Giaccio, G. P., 22  
 Watanabe, Arthur S. Modifications of the systematic approach to answering drug information requests (letter), 472  
 Weinberger, Miles, see Hendeles, Leslie, 49, 169, 926, 1456  
 Weinstein, Marvin M. Formulation of a stable trace element solution for TPN (letter), 1620  
 Welch, Dennis Chelating agent in non-USP calcium gluconate injection (letter), 174  
 Welco, Alan see Henry, R. Scott, 673  
 Welco, Alan D. see also Sturgeon, Roy J., 388  
 Wertheimer, Albert I. see Stergachis, Andreas S., 1072  
 Wesolowski, Cheryl see Traub, Scott, 464  
 West, Dennis P. see Witte, Kenneth W., 820  
 Westfall, Lawrence K. Potentiation of warfarin by tetracycline (letter), 1620  
 White, Sara J. Participating in the legislative alert system (letter), 160  
 White, Thomas J. III see Burkart, Gilbert J., 222  
 Whitehead, William see Rehder, Terry L., 379  
 Wightkin, William T. Stress ulcer: Pathophysiology and prevention, 1651  
 Willcox, Gordon S. see Card, Vincent, 334  
 Williams, Robert B. see Sigell, Leonard T., 1206  
 Wilson, H. David see Foster, Thomas S., 858  
 Winek, Charles L. Book review, 283  
 Winely, Carl L. see Bornstein, Michael, 98  
 Wiser, Thomas H. see Roffman, David S., 1105  
 Wiser, Thomas H. see also Westfall, Lawrence K., 1620  
 Witte, Kenneth Audit of an oral anticoagulant teaching program, 89  
 Witte, Kenneth W. Drug regimen review in skilled nursing facilities by consulting clinical pharmacists, 820

- Witte, Kenneth W. Effect of pharmacist consultation on rational antimicrobial therapy, 829  
 Wong, Lai see Hendeles, Leslie, 1496  
 Wood, Warren A. Adding insulin to LifeCare flexible containers (letter), 1617  
 Woodman, Tracy see Marion, Athan, 341  
 Wyant, Susan L. see McKenney, James M., 824

## Y

- Yee, Gary C. see Bond, William S., 74  
 Yosselson-Superstine, Shimona Drug interference with the phosphotungstate uric acid test (letter), 1458  
 Yosselson-Superstine, Shimona Drug interferences with tests performed by a 12-channel autoanalyzer, 1333  
 Yosselson-Superstine, Shimona Theophylline interference with the phosphotungstate uric acid test, 1522  
 Yost, Richard L. see Ives, Timothy J., 683  
 Young, W. Wayne Pharmacists' notations in patients' charts (letter), 16  
 Young, W. Wayne Interpretation of research data: Exploratory data analysis, 1394

## Z

- Zacchilli, Cynthia Information needed on pharmacy-based i.v. teams (letter), 625  
 Zeisler, John A. Jr. In support of the kinetic model for intravenous heparin infusion (letter), 637  
 Zeisler, John A. Jr. Intraventricular gentamicin administration (letter), 926  
 Zellmer, William A. Book review, 296  
 Zellmer, William A. Editorials, 50, 481, 642, 801, 1059, 1487, 1629  
 Zellmer, William A. News, 590, 738, 886  
 Zelnio, Robert N. Data collection techniques: Mail questionnaires, 1113  
 Zenk, Karin E. Dosage calculations for drugs administered by infusion (letter), 1304  
 Zilz, David A. ASHP and the issues, 972  
 Zuidema, J. N-substituted theophylline derivatives (letter), 169

## Advertising Index

## A

- Abbott Laboratories  
 Erythrocin Piggyback, 616-617, 794-795, 922-923, 1152-1153, 1184-1185, 1478-1479  
 IVEK-HP, 313, 469, 784  
 IVEK-2, 1058, 1259, 1555  
 Affiliated Hospitals Center, Inc.  
 Position Available, 905  
 Akro-Mile, Inc.  
 Pharmacy Equipment, 1685  
 American Critical Care, Division of American Hospital Supply Corporation  
 Hespan, 1056-1057, 1268-1269, 1288-1289  
 Institutional, 596-597, 736-737, 796-797  
 Intropin, 1570-1572  
 American Critical Care see also Arnar-Stone Laboratories  
 American Pharmaceutical Association  
 Handbook of Nonprescription Drugs, 1154  
 Pediatric Dosage Handbook, 1715  
 American Red Cross  
 CPR Training, 414  
 American Society for Parenteral and Enteral Nutrition  
 Fifth Clinical Congress, 1626  
 American Society of Hospital Pharmacists  
 Continuing Education, 256  
 Handbook on Injectable Drugs, 769  
 Medication Teaching Manual, 305, 758  
 1981 Annual Meeting, 1606  
 Oncology Books, 1042  
 Position Available, 600, 609, 1041  
 Ames Color-File, Division of Ames Safety Envelope Company  
 Kompres, 1309  
 Antigen Supply House, Inc.  
 Skin Test Antigens, 780, 1010, 1167, 1412, 1549  
 Arnar-Stone Laboratories, Division of American Hospital Supply Corporation  
 Bretlyol and Intropin, 170-174  
 Intropin, 38-39, 336-337, 404-405  
 Arnar-Stone Laboratories see also American Critical Care  
 ASCO  
 Uni-Dose System, 1721  
 Ascot Hospital Pharmaceuticals, Inc.

- Institutional, 1431  
 Astra Pharmaceutical Products, Inc.  
 Bricanyl, 1301, 1442, 1597  
 Xyllocaine Unit Dose, 1135-1136, 1283-1284, 1415-1416, 1559-1560, 1699-1700  
 Ayerst Laboratories, Division of American Home Products Corporation  
 Dermoplast, 443, 732, 781  
 Inderal, 28-30, 288-290, 324-326, 580-582, 610-612, 868-870

## B-C

- The Baker Company  
 Laminar Flow Hoods, 1687  
 BDM Information Systems Ltd.  
 Computer Systems, 1665  
 Becton-Dickinson, Division of Becton, Dickinson and Company  
 Glaspak Syringe, 36, 1413  
 The Bermuda Hospitals Board  
 Position Available, 1172  
 Beth Israel Medical Center  
 Position Available, 857  
 Breon Laboratories, Inc.  
 Brookline, 111-114, 249-252  
 Bristol Laboratories, Division of Bristol-Myers Company  
 Bristoject, 444-445, 630-631, 770-771, 916-917, 1126-1127, 1162-1163, 1406-1407  
 Cefadyl, 433, 477, 743, 751, 1024, 1047, 1181, 1393, 1577, 1619  
 Kantrex, 17-18  
 Mexate, 123-125, 293-295, 327-329, 577-578, 619-620, 875-876, 911-912, 1257-1258, 1419-1420, 1463-1464  
 Barron Medical Inc., A. B. Braun of America Company  
 Additive Cap, 51, 599, 1193, 1583  
 Hyperal Transfer Set, 1716  
 Multi-Ad System, 156-157, 314-315, 606-607, 921, 1427  
 Secondary I. V. Set, 799, 1111  
 Burroughs Wellcome Company  
 Empirin  $\bar{c}$  Codeine, 27, 1439, 1628  
 Lanoxin, 275-276, 575-576, 1537-1538, 1683-1684  
 Viroptic, 752-754, 908-910, 1146-1148

- Children's Hospital National Medical Center  
 Positions Available, 1457  
 Connaught Laboratories Inc.  
 Tubersol, Jan-OBC, 309, Mar-OBC, 482, 709, 800, 929, Aug-OBC, 1177, 1291, 1459, 1611  
 Critikon, Inc.  
 Institutional, 181-184  
 Cutter Biological, Division of Cutter Laboratories, Inc.  
 HyperHep, 175-176, 347-348, 475-476, 635-636, 879-880, 925-926, 1137-1138  
 Plasbumin, 144-146, 422-424  
 Plasmanate, 467-468  
 Cutter Medical, Division of Cutter Laboratories Inc.  
 Institutional, 1295, 1297  
 Pureflo, 446, 725, 1019, 1293

## D-F

- Dennison Manufacturing Company  
 Secur-A-Seal Bags, 1178, 1377  
 Drug Intelligence Publications, Inc.  
 Publications, 1554  
 Elkins-Sinn, Inc., Subsidiary of A. H. Robins Company  
 Gentamicin, 1440-1441, 1702-1703  
 Hep-Lock, 335, Nov-OBC, Dec-OBC  
 Hydroxyzine, Apr-OBC, May-OBC, Jun-OBC, Jul-OBC, 1060, Sep-OBC, Oct-OBC  
 Lidocaine, 13, Feb-OBC  
 European Center for Pharmaceutical Documentation  
 Cedpharm, 540  
 Florida Agricultural and Mechanical University  
 Symposium, 14  
 E. Fougere & Company, Division of Byk-Gulden, Inc.  
 Efdone, 301, 893  
 Foilpac, 318, 1159, 1568  
 Institutional, 1435  
 Nystatin-Neomycin-Gramicidin-Triamcinolone Cream and Ointment, 595  
 Surgilube, 603

## G-I

**Geigy Pharmaceuticals, Division of Ciba-Geigy Corporation**  
Lopressor, Jan-IPC, Feb-IPC, Mar-IPC, Apr-IPC, May-IPC  
Unit Dose, Jun-IPC, Jul-IPC, Aug-IPC, Sep-IPC, Oct-IPC, Nov-IPC, Dec-IPC  
**Geisinger Medical Center**  
Position Available, 885  
**Gem Refrigerator Company**  
Refrigerator, 110, 278, 421, 570, 701, 892, 960, 1122, 1250, 1408, 1462, 1722  
**HPI Hospital Pharmacies**  
Institutional, 1417, 1449  
Position Available, 1243  
**Hurley Medical Center**  
Position Available, 1103  
**IMED Corporation**  
Accudot, 1304A-1304B, 1552A-1552B, 1621-1624  
IV Pump, 604-605, 782-783, 1020-1021, 1034-1035, 1423-1423, 1588-1589  
Volumetric Infusions Pumps, 25  
**International Pharmaceutical Federation**  
Membership Recruitment, 850  
**I.T.L. Industries, Inc.**  
Med-A-Counter Mark II, 1724  
**IVAC Corporation**  
IVAC 230 Controller, 178-179, 456-457, 628-629, 762-763, 1132-1133, 1270-1271, 1282-1283, 1468-1469, 1704-1705  
IVAC 630 Pump, 8-9  
**Ives Laboratories, Inc.**  
Cerubidine, 906-907, 1036-1037

## J-L

**Jackson Memorial Medical Center**  
Position Available, 1255, 1701, 1712  
**Jewett Refrigerator Company, Inc.**  
Refrigerators, 552, 1043, 1414  
**Jobst Institute, Inc.**  
Anti-Em/GP, 931, 1713  
**Kewaunee Scientific Equipment Corporation**  
Institutional, 282  
**Knoll Pharmaceutical Corporation**  
Calcium Ion Antagonists, 1567, 1587  
**Lee & Febiger**  
Publications, 890  
**Lederle Laboratories, Division of American Cyanamid Company**  
Asendin, 1446-1448, 1598-1600  
Continuing Education, 569, 1008, 1310  
**Lifemark Corporation**  
Grant Awards Program, 345, 1467  
Pharmacy Awards, 899  
Positions Available, 874, 1180, 1426, 1545, 1671  
**Elil Lilly and Company**  
Institutional, 32-33, 154-155, 338-339, 462-463, 730-731, 776-777, 1011-1013, 1139-1141, 1173-1175, 1367-1369, 1475-1477, 1607-1609  
Kefzol, 6, 285, 323, 471, 615, 867, 1031, 1265  
**Lionville Systems Inc.**  
Documed, 1169, 1561  
Med Cart 600, 1275  
**Lyne Laboratories, Inc.**  
Pathology Solution, 1612  
**Lyphe-Med, Inc.**  
Sterile Injectable Products, 1666

## M

**Machick, Division of C. R. Bard, Inc.**  
Medication Carts, 15  
Medication Management Systems, 1581, 1719  
**Market Forge**  
Medication Carts, 461  
**McGaw Laboratories, Division of American Hospital Supply Corporation**  
Accumed, 136-137, 158-160, 1298-1300  
EPIC, 1276-1277  
Hepatic Aid, 1409  
Institutional, 41-46  
**Mead Johnson Pharmaceutical Division, Mead Johnson and Company**  
Mucomyst, 120-122  
**Medi-Dose, Inc.**  
Medi-Dose/Medi-Cup System, 37, 307, 470, 891, 1041  
**Merrell-National Laboratories, Division of Richardson-Merrell Inc.**  
Yutopar, 1302-1303, 1472-1473  
**Miami Heart Institute**  
Position Available, 701  
**Herman Miller, Inc.**  
The Co/Struc System, 3, 161, 455, 1287  
**Millipore Corporation**  
Addi-Chek, 465  
Miller, 115, 117, 119, 279, 281, 283, 435, 437, 439, 622, 739, 746, 885, 887, 889, 1005, 1007, 1009, 1121, 1123, 1125, 1249, 1251, 1253, 1385, 1387, 1389  
**Monosject Division of Sherwood Medical, A Brunswick Company**  
Needles and Syringes, 1601-1604  
**MPL, Inc.**  
Unit Dose Vials, 426, 571

## N-P

**National Institutes of Health**  
Positions Available, 1457  
**New England Medical Center Hospital**  
Positions Available, 1545  
**Northeastern University**  
Positions Available, 1680  
**Omnimed, Inc.**  
Beam Cabinets, 1252, 1470  
Drug Kits, 1421  
Perinex, 434, 568, 734, 1252, 1421, 1470  
**Ongwanda Hospital**  
Psychopharmacology Seminar, 1167  
**Organ Pharmaceuticals, Division of Organon, Inc.**  
Hexadrol, 48, 297, 415, 549, 643, 894, 934, 1104, 1194, 1312, 1550, 1630  
**The Owen Company**  
Positions Available, 118, 300, 420, 548, 716, 877, 928, 1044, 1182, 1434, 1536, 1711  
**Parks, Davis and Company, Division of Warner-Lambert Company**  
Dispos-a-Med System, 705-706, 765-768, 961-964  
Documed, 352, 480, 640  
Uni-Use, 10-11, 286-287, 316-317, 452-453, 725-729, 778-779, 1014-1015, 1150-1151, 1180-1161, 1556-1557, 1706-1707  
**Pharmaceutical Associates, Division of Beach Products, Inc.**  
Generic Liquid Pharmaceuticals, 865  
**Pharmaceutical Consultant Services, PA**  
Seminar, 110  
**Pharmaseal Laboratories, Division of American Hospital Supply Corporation**  
Pharm-Aide, 351, 927, 1155, 1563  
**Phillips Roxane Laboratories, Inc., A Boehringer Ingelheim, Ltd. Company**  
Acetaminophen/Codeine, 1296, 1445  
Isoetharine, 20-21, 148-149, 418-419, 1278, 1565  
Liquid Unit Dose, 162-163, 330-331  
Milk of Magnesia, 1433, 1471, 1590  
Morphine, 450-451, 632-633, 872-873, 914-915, 1032-1033, 1266  
**Production Equipment, Inc.**  
Counters, 247, 449, 769, 1051, 1353, 1595  
**PSG Publishing Company, Inc.**  
Publications, 1465, 1710  
**The Purdue Frederick Company**  
Betadine, 116, 438, 639, 1027, 1179, 1485

## R-T

**Roche Laboratories, Division of Hoffmann-La Roche Inc.**  
Institutional, 34-35, 266-267, 396-397, 565-567, 717-719, 881-883, 1244-1245, 1354-1355, 1578-1579  
Valium, 536, 745, 802, 997, 1112, 1197  
**Roche Products, Inc.**  
Dalmans, 4-5, 332-333, 458-459, 726-727, 760-761, 1022-1023, 1142-1143, 1170-1171, 1410-1411, 1450-1451, 1694-1695  
**RxCount Corporation**  
Counting Equipment, 1405  
**Sandoz Pharmaceuticals**  
Institutional, 573, 788, 1124, 1399, 1662  
SandoPak, 143  
**Schering Corporation**  
Garamycin, 166-168, 473-474, 773-774, 1053-1054, 1429-1430  
USC Postgraduate Course, 1050  
Vanceril, 302-304  
**Shadyside Hospital**  
Position Available, 1552  
**Sigmamotor, Inc.**  
Sigma 5000, 19  
**Smith Kline & French Laboratories, Division of SmithKline Corporation**  
Institutional, 710, 832  
Tagamet, 918-919  
**E. R. Squibb & Sons, Inc.**  
Corpard, 150-152, 342-344, 584-586  
Position Available, 449  
**Stanford University Hospital**  
Positions Available, 704  
**SystemModules, Division of General Equipment Manufacturers**  
Institutional, 134, 186, 416, 563, 747, 786, 1016, 1120, 1247, 1486  
**Telaugraph Corporation**  
OmniFax, 1483  
**Texas Society of Hospital Pharmacists**  
Annual Seminar, 126  
**Travenol Laboratories, Inc.**  
Positions Available, 1391, 1564  
Travasorb, 1189-1192, 1401-1404, 1453-1456, 1680-1692  
Vialflex, Jan-IBC, Feb-IBC, Mar-IBC, Apr-IBC, May-IBC, Jun-IBC, Jul-IBC, Aug-IBC, Sep-IBC, Oct-IBC, Nov-IBC, Dec-IBC

## U

**United Hospital**  
LEM Emergency Cart, 1613  
Medication Cart Systems, 1183, 1480, 1617  
Night Pharmacy, 1187, 1281, 1481  
Pharmacy Equipment, 466, 479, 741, 878, 905, 1134, 1294  
Unit Dose Carts, 637, 758, 924, 1131  
Unit Dose Medication Systems, 292  
**United States Pharmacopoeial Convention**  
USP-DI, 1575, 1681  
**University Hospitals of Cleveland**  
Position Available, 1582  
**University of Arkansas**  
Positions Available, 589  
**University of California Medical Center, San Diego**  
Position Available, 742  
Fellowship, 255  
**University of California, San Francisco**  
Symposium on Street Drugs, 1398  
**University of Cincinnati Hospital**  
Positions Available, 558, 1110  
**University of Connecticut**  
Position Available, 589  
**University of Iowa**  
Clinical Pharmacy Fellowship, 26  
**University of Iowa Hospitals and Clinics**  
Positions Available, 722, 1248  
Residency Positions, 26  
**University of Maryland**  
Position Available, 1186  
**University of Michigan Hospitals**  
Positions Available, 572, 744  
**University of Southern California**  
Positions Available, 300, 1445  
**University of Tennessee Center for the Health Sciences**  
Position Available, 1391  
**The Upjohn Company**  
Institutional, 792-793  
Cleocin, 900-902, 1128-1130, 1260-1262  
**Upsher Smith Laboratories, Inc.**  
Acetaminophen Uniserat, 52, 188, 354, 644, 1198, 1488  
**USV Laboratories, Division of USV Pharmaceutical Corporation**  
M.V.I. 12, 1284-1285, 1460-1461, 1696-1697

## V-Y

**Victoria General Hospital**  
Pharmacokinetics '80, 1018  
**Virginia Mason Hospital**  
Pharmacy Computerized Information System RFP, 1286  
**Warner-Lambert Company**  
Position Available, 540  
**Waterloo Industries**  
Med-Cart, 31, 298, 436, 472, 895, 1049, 1267, 1292, 1482, 1615  
**West Virginia University Hospital**  
Position Available, 133  
**Wheaton**  
I. V. Additive Pump Chamber Assembly, 721, 1045, 1723  
Uni-Dose, 291, 321, 913, 1379  
Unipense, 859  
Zippettes, 341  
**White Publishing Company, Inc.**  
National Drug List, 723, 871, 1025, 1307, 1673, 1672  
**Winthrop Laboratories**  
Carpucet, 23, 177, 349, 583, 606, 1145, 1164, 1424, 1708  
**Wyeth Laboratories**  
Tubex, 425, 427, 429, 431, 587, 589, 591, 593, 621, 623, 625, 627, 785, 787, 789, 791  
**York Hospital**  
Position Available, 1281

